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Abstract 
Background 
Cystic fibrosis (CF) is an autosomal recessive, multisystem disorder affecting ion transportation 
across epithelial membranes. Respiratory complications are the leading cause of morbidity and 
mortality and CF lung disease is characterised by repeated infections leading to inflammation 
and fibrosis of the lungs. 
Early and accurate identification of respiratory pathogens is essential to enable timely and 
efficacious treatment of infections. This is ensured by obtaining microbiology samples at each 
clinic visit.  The gold standard is sputum culture; however, many children are unable or unwilling 
to expectorate. In non-expectorating children, cough swabs (CS) or cough plates (CP) can be 
used. Previous studies comparing the performance of these two samples are conflicting.   
Aims 
The primary aim of this study is to compare yield of respiratory pathogens identified by CS and 
CP in non-expectorating children with CF.  
Secondary objectives include comparing the types of organisms identified by CS and CP and 
assessing whether lung function, Body mass index (BMI) centile, age and gender affect whether 
a CS or CP is more likely to identify a pathogen.  
Methods 
Non-expectorating children with CF attending Shrewsbury and Telford NHS Trust provide CS 
and CP samples at each outpatient visit. The results of the paired cultures from November 2013-
2018 were analysed. Samples positive for non-pathogenic organisms including yeast, candida 
and Bacillus species were excluded. 
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Results 
We identified 663 paired CS and CP samples from 38 patients. Mean (SD) age was 9.9 (4.7) years. 
The CS and/or the CP was positive for a respiratory pathogen on 118 (18%) of the paired 
samples. This included 66 (10%) CS and 87 (13%) CP samples. Only 27 (23%) of the paired 
samples with a positive culture identified the same pathogen(s) on both CS and CP. Number 
needed to sample: in this sample 13 children needed both CS and CP samples to identify one 
additional respiratory pathogen compared to CS alone. McNemar’s test (p=0.028) and the 
generalised estimating equation (p=0.020) suggest that the difference in CS and CP 
performance was statistically significant. However, the magnitude of this difference was so 
small whether it is clinically significant remains to be determined.  
CS identified a greater variety of pathogens compared to CP, identifying 6 additional pathogens 
not cultured on CP. Lung function was the only significant predictor of both CS and CP positivity 
on multivariable analysis. BMI centile also had a statistically significant relationship with CP 
being positive for pathogens on multivariable analysis. 
Conclusions 
The rate of respiratory pathogen isolation was similar for CS and CP samples. Simultaneous use 
of CP and CS identified more pathogens than either sampling method alone. Further studies are 
required to investigate if similar improvements could be achieved by obtaining duplicate CS or 
CP samples.  
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1.0 Literature Review 
1.1 Background 
Cystic fibrosis (CF) is an autosomal recessive condition causing defective ion transportation 
across epithelial surfaces throughout the body. It is a multisystem condition, but most 
significantly affects the lungs, pancreas, reproductive organs and gastrointestinal tract. CF is of 
great clinical relevance as it is the most common life limiting condition in Caucasian populations. 
A diagnosis of CF only a few decades ago was equated to a death sentence in a patient’s early 
twenties; this has changed alongside the rapid growth of understanding around the condition. 
The significant improvement in prognosis has been determined by advances in both diagnostic 
tests and treatment options, a trend which continues today.   
1.2 History of CF  
Although understanding of the pathology and aetiology of CF has only occurred relatively 
recently, CF is far from a new entity. Descriptions thought to be linked to CF date back as far as 
the middle ages, where babies whose skin tasted salty were thought to be hexed and cursed 
with an early death (1). From the fifteenth century onwards, there are anecdotal reports of 
characteristic features of CF such as steatorrhoea, with the first autopsy thought to describe CF 
occurring in 1595 (2). It is even postulated that romantic composer, Frederic Chopin, may have 
had CF (3). 
During the twentieth century, CF began to be recognised as a disease of both the lungs and 
pancreas. Dorothy Andersen’s landmark paper in 1938 “Cystic fibrosis of the pancreas and its 
relation to coeliac disease” finally gave the disease of folklore a name (4). Andersen was a 
paediatric pathologist and identified CF by observing fibrocystic changes in the pancreas at post 
mortem. Andersen went onto describe the Mendelian inheritance of CF almost a decade later 
(5).  
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Other important landmarks in our understanding of CF include Gibson and Cooke’s discovery of 
sweat testing in the 1950s as an alternative to invasive trypsinogen testing (6). Gibson and 
Cooke’s discovery was prompted by di Sant'Agnese’s recognition of abnormal salt loss in sweat 
of patients with CF (7). Di Sant’Agnese’s work on electrolyte abnormalities followed observation 
of increased heat prostration of patients with CF at Columbia Hospital New York during a 
heatwave.  Sweat testing is still considered the gold standard in diagnosing CF over half a 
century later (8).  
The 1950s also saw great advancements in the treatment of CF. Physiotherapy began to be used 
in the United Kingdom (UK) as an important component of routine CF care (9). Physiotherapy 
was introduced by Dr Winifred Young to CF patients from the time of diagnosis, at her clinic at 
the Queen Elizabeth Hospital in London, although not all physicians at the time were convinced 
of the value of physiotherapy (10). 
Physiotherapy was also adopted as part of a more holistic approach to CF care pioneered by 
LeRoy Matthews in the United States (US). His prophylactic regimen included regular 
microbiological testing, which guided targeted antibiotic treatment, nebulised treatment and 
the use of mucolytics and decongestants (11). Much of his practice is still commonplace in CF 
clinics today. Another advancement in treatment in the 1950s was the introduction of a high 
fat diet with oral pancreatic enzyme supplementation.  This approach, instigated by Dr Douglas 
Croizer, was contrary to previous dietary advice given to patients with CF (12). However, his 
findings of improved nutritional status and survival when adopting a high fat, high calorie diet 
in CF still hold true today and are another cornerstone of CF management. Further advances in 
the CF diet occurred in the UK, where Dr Archie Norman’s unit at Great Ormond Street Hospital 
provided evidence that pancreatic enzyme supplementation was beneficial for children with CF 
(13).  
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The UK and the US were not the only countries to make strides in CF care in the 1950s. In 1953, 
Dr Charlotte Anderson started a CF clinic in Melbourne. Dr Anderson contributed to knowledge 
surrounding both coeliac disease and CF including the use of bronchodilators in CF (14). She 
went on to become Professor of Paediatrics in Birmingham from 1968 to 1980 (10).  
Advances in CF treatment continued in the 1960s and 1970s. Dr Margaret Mearns was a pioneer 
of CF care, and demonstrated that prompt and effective use of antibiotics significantly improved 
respiratory outcomes in children with CF (15). She also cautioned the use of prophylactic anti-
staphylococcal antibiotics as she felt they may lead to increased infections with Pseudomonas 
aeruginosa (16), an opinion that is still debated today (17).  
Decade after decade, understanding of CF has continued to grow (2). The 1980s saw the 
identification of the most common genetic mutation which causes CF (18–20), lung 
transplantation in patients with advanced CF (21) and the creation of the newborn screening 
test for CF in 1983 (22), although this was not to be adopted throughout the UK until 2007. 
Multidisciplinary CF specialist care also began to be developed in the UK, with Dr James 
Littlewood’s centre at Leeds being an example of this (10). Littlewood and his team contributed 
greatly to CF knowledge, including research on colomycin (23), nutrition (24) and many other 
elements of CF care (10). Littlewood went on to play numerous important roles in the CF Trust, 
including being Chairman of the Trust from 2003 to 2011 (10).  
Other notable discoveries in CF management include the introduction of nebulised antibiotics 
and mucoactive agents, both of which were developed in the 1990s. Recombinant human 
DNase (rhDNase) is a mucoactive agent. It reduces the viscosity of sputum in patients with CF, 
improving efficacy of physiotherapy as more secretions can be shifted (25). Use of rhDNase has 
been shown to reduce frequency of pulmonary exacerbations and improve lung function (26). 
Nebulised hypertonic saline, another mucoactive medication, was also trialled as a therapy for 
CF in the 1980s (27) and 90s (28). Hypertonic saline aids liquefication of mucus, increases 
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mucociliary clearance (29), and has been shown to improve lung function in patients with CF 
(30). 
Alongside physiotherapy and mucoactive agents, antibiotics form an integral part of CF 
pulmonary care. Inhaled tobramycin was first trialled in 1999 as an intermittent treatment for 
CF patients with chronic Pseudomonas aeruginosa infection (31). Colistimethate sodium had 
previously been used in Europe to treat P. aeruginosa infection. Tobramycin showed an increase 
in lung function, reduced density of P. aeruginosa infection and reduced hospital admissions 
when compared to placebo. Inhaled tobramycin also showed no detectable ototoxic or 
nephrotoxic side effects. Colistin, tobramycin and aztreonam are now all used as nebulised 
antibiotics in patients with CF. Nebulised anti-pseudomonal antibiotics are also used in the 
eradication of new growths of P. aeruginosa. They can be used independently of or in 
conjunction with oral or intravenous antibiotics to eradicate P. aeruginosa and prevent chronic 
infection and consequent airway remodelling.  
Research into genes therapies began in the 1990s and 2000s. In 2011 and 2012, CF 
transmembrane conductance regulator (CFTR) modulators, a treatment option for patients with 
specific mutations were developed. Advances in treatment continue to be discovered, with 
clinical trials in 2018 for triple therapy now showing promise (32,33). Figure 1 summarises some 
of the key landmarks in CF history since 1938. 
 
Figure 1- A timeline (not to scale) detailing some of the important landmarks in CF history 
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1.3 Epidemiology of CF  
In 2017, over 10,400 patients were living with CF in the UK (34). Over half of those living in the 
UK with CF are adults, a reflection on the increasing life expectancy with CF. It has been shown 
that 1 in 25 Northern Europeans carry one of the many genes associated with CF and there is 
an incidence of CF occurring in 1 in every 2,500-3,500 births in Northern Europe (35). 
1.4 Genetics and Classification of CF  
In the 1980s, one of the greatest achievements of CF research occurred in the discovery of the 
causative gene for CF. The first major breakthrough was in 1985, when Tsui and colleagues 
identified the locus of the CF gene to be on the long arm of chromosome 7 (36). In 1989, the 
long-awaited discovery of the CFTR gene which causes CF occurred, alongside discovery of the 
most common mutation: Phe508del. This gene is present in approximately 70% of patients in 
Northern Europe with CF (18–20). The Phe508del gene is less common elsewhere. The gene 
itself is known as the CFTR gene as the protein product of this gene is key in transport of chloride 
and sodium ions across epithelial cell membranes.  
Over 2000 documented mutations of the CFTR gene have now been isolated (37). Due to this 
large genotypical variance there is also great heterogeneity in the clinical features of patients 
with CF. Classification systems have been developed to anticipate the clinical outcome based 
on the genotype of the patient and, in the age of gene targeted therapies, help to guide 
treatment choices.  
The first classification system was developed by Welsh and Smith in 1993 (38), who initially 
proposed four classes. Since then the classification system includes six classes (39). See Table 
1.1 and Figure 2.  
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Table 1.1 - The six-class classification of CF 
Class Genetic Defect Functional Consequence Common mutations 
I Nonsense, frameshift and large 
deletions 
Little or no functional 
CFTR produced 
GF42X, R553X, 
W1282X, R1162X 
II Some missense mutations and 
in-frame deletions 
Prevent CFTR 
transportation to the cell 
surface resulting in few 
functional CFTR’s. 
 
Phe508del, N1303K, 
R1066C 
III Missense mutations leading to 
defective regulation of the 
CFTR channel. 
Gating defect – reduced 
opening probability of 
CFTR channel. 
G551D, G178R, 
G551S, G1349D 
IV Missense mutations leading to 
defective conductance through 
the CFTR channel. 
Impede conductance of 
ions through the channel. 
R117H, R334W, 
R347P, R1070W 
V Promoter or splicing 
abnormalities that do not alter 
the CFTR protein but 
significantly reduce its 
abundance. 
Reduced amounts of 
normal CFTR protein. 
 
A455E, D565G, 
2789+5G->A 
VI A variety of mutations which 
increase the turnover of CFTR 
protein. 
Normal CFTR protein is 
produced but it is unstable 
and degraded quickly. 
120Δ23, N287Y 
 
It is important to note that Phe508del, the most common mutation, produces more severe 
disease than some mutations.  Classes I to III typically produce more severe disease whereas 
classes IV to VI typically have a milder phenotype (40).  
Although identifying an individual’s genotype is important, it is common for children with the 
same genotype to have very different clinical progression. It is not only the CFTR mutation that 
affects outcome but there is also a major role for environmental factors and gene modifiers 
(41,42). Therefore, clinicians cannot predict with confidence the course of disease based solely 
on genotype. 
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1.5 Pathogenesis of CF  
Regardless of the individual gene mutations, the pathogenesis of CF is broadly the same; there 
is loss of function of the CFTR protein. The CFTR protein is an ion channel present in epithelial 
surfaces throughout the body (43). In simplistic terms, the CFTR was initially thought of as a 
chloride ion channel and its absence or dysfunction therefore affects the transportation of 
chloride ions across epithelial surfaces. This explains the high levels of chloride ions present in 
sweat, that form the basis of CF sweat test.  
The CFTR channel may also be involved in chloride-bicarbonate exchange. This is important as 
alterations in bicarbonate concentration have an impact on several important physiological 
elements: pH, mucin unfolding, innate immunity and gastric acid neutralisation (44). The 
Figure 2 - A graphic to demonstrate the different classes 
of CFTR mutation. 
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transport of chloride ions through CFTR has synergistic effects on ion transportation through 
other channels, particularly sodium transportation (43).  
The culmination of this alteration in ion transportation is the presence of viscous mucus in both 
the airways and gastrointestinal tract in patients with CF. This is responsible for many of the 
clinical feature seen in CF.  
1.6 Clinical Picture 
1.6.1 Respiratory  
Although CF is a multisystem disorder, respiratory symptoms usually dominate the clinical 
picture. Respiratory complications are by far the leading cause of morbidity and mortality. The 
care of patients with CF is usually coordinated by respiratory physicians. CF lung disease is 
characterised by recurrent respiratory infections leading to chronic inflammation and 
parenchymal damage causing progressive respiratory failure.   
Changes to respiratory secretions and reduced mucociliary clearance lead to an increased 
susceptibility to infection. Typical organisms include: Haemophilus influenzae, Staphylococcus 
aureus, Burkholderia cepacia complex and most significantly Pseudomonas aeruginosa. 
Infection with P. aeruginosa is of particular clinical relevance as it may lead to chronic infection 
and has worse prognostic implications. Further details on respiratory infections, their detection, 
management and clinical significance will be discussed in chapter 2.   
1.6.2 Pancreatic 
In the same way that viscous secretions affect the respiratory system, so can they affect the 
pancreas. CFTR is abundantly expressed on pancreatic acinar cells (45) and is responsible for 
the transport of chloride and bicarbonate to maintain an alkaline fluid in a healthy pancreas. 
The absence of CFTR in the pancreas results in a high concentration of protein and low volume 
of fluid making it more viscous (46), this is known as mucoviscidosis. The small ducts of the 
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pancreas become blocked and plugged with the viscous fluid in utero, and over time this leads 
on to large duct obstruction. Obstruction is followed by destruction, inflammation, fibrosis and 
fatty deposits within the pancreas (47).  
The progressive destruction of pancreatic tissue in the majority of patients with CF leads to 
pancreatic exocrine insufficiency.   Consequently, insufficient levels of digestive enzymes reach 
the gastrointestinal tract, causing malabsorption especially affecting the absorption of fats and 
fat-soluble vitamins – vitamins A, D, E and K. Clinically, malabsorption can manifest as 
steatorrhoea, failure to maintain length and weight centiles and in severe cases may lead to 
malnutrition.   
However, not all patients with CF go on to develop pancreatic insufficiency. Approximately 15% 
continue to produce sufficient enzymes to allow for normal digestion. Faecal elastase testing is 
used to screen patients with CF for pancreatic insufficiency (48). Pancreatic status has been 
linked to genotype (19,49) with more severe mutations (classes I-III) more frequently exhibiting 
insufficiency and milder mutations (Classes IV to VI) typically being pancreatic sufficient. It is 
important to note that even though a patient may be clinically pancreatic sufficient, damage to 
the pancreas is still occurring and despite sufficiency remain at an increased risk of developing 
pancreatitis (50).  
1.6.3 Endocrine  
As well as causing destruction of the exocrine pancreas, over time CF can also impede the 
function of the endocrine pancreas due to destruction of the islets of Langerhans which produce 
insulin. This contributes to the development CF related diabetes (CFRD). Abnormalities in insulin 
resistance and glucose metabolism are also contributing factors. CFRD develops insidiously and 
many patients may be asymptomatic at presentation. Presenting features can include: polyuria, 
polydipsia, weight loss or failure to maintain or gain weight, poor growth, delayed or slowed 
progression of puberty and decline in lung function (51).  
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CFRD is a separate entity to type I and type II diabetes mellitus, although it shares features with 
both types. As CF prognosis has improved, so too has the prevalence of CFRD. Prevalence 
increases significantly with age and 40-50% of adults with CF have CFRD (52). Females appear 
more susceptible to CFRD at a younger age (53). Individuals who are homozygous Phe508del 
are at an increased risk for CFRD, showing that some CF genotypes have a higher risk of CFRD 
than others (54). Screening for CFRD via oral glucose tolerance testing (OGTT), is usually 
performed annually from the age of 10 as part of their annual review (55,56). Detection of CFRD 
is not only important in optimising control of blood glucose but also for optimising lung function, 
as patients with CFRD are also more likely to have poor respiratory function (57).  
CFRD is the most common endocrine abnormality associated with CF, but additional endocrine 
complications include bone disease and male hypogonadism. The causes of CF-related bone 
disease are multi-factorial, but include: malabsorption, low vitamin D levels, corticosteroid use, 
alteration in growth and sex hormone axis’s and genotype (58). Approximately 23% of patients 
with CF have osteoporosis and 38% have osteopaenia (59). Monitoring bone density from a 
young age forms an important part of CF care, with screening first occurring in children over the 
age of 8 who meet certain criteria (60). This is important as early recognition and treatment 
with vitamin supplementation, weight gain and weight bearing exercise can improve bone 
density and significantly reduce the risk of fragility fractures (61). As with CFRD, the presence 
of CF-related bone disease is also linked to poor lung function.  
Low levels of testosterone have been found in 1 in 4 males with CF (62). This can further 
contribute to CF-related bone disease. Hypogonadism is not routinely screened for in CF but 
should be considered in males who have low bone mineral density.  
1.6.4 Gastrointestinal  
CFTR is present in epithelial cells throughout the gastrointestinal and hepatobiliary systems (63) 
and altered ion transportation in these systems may manifest clinically as meconium ileus, distal 
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intestinal obstruction syndrome (DIOS), constipation and liver cirrhosis. Meconium ileus can be 
the first manifestation of CF and is considered pathognomonic of CF. It occurs in approximately 
20% of newborn patients with CF. In meconium ileus, viscid meconium obstructs the intestines, 
typically at the terminal ileum, and neonates are unable to pass stool. Healthy babies will 
normally pass meconium within the first 24 hours. In cases of meconium ileus, proximal loops 
of bowel dilate creating the clinical picture of obstruction. This can be further complicated by 
intestinal atresia, volvulus formation or perforation (64). As with many of the complications of 
CF, genetics play an important role, with individuals with Class I-III mutations being at higher 
risk of having meconium ileus.  
In later life, a similar complication of intestinal obstruction as a result of viscous bowel contents 
can occur, known as DIOS. In DIOS, viscid bowel contents build up typically at the terminal ileum 
or proximal colon and can cause a partial or complete obstruction (65). DIOS is defined as acute 
complete or incomplete faecal obstruction in the ileocaecum (66). Treatment with stool 
softening laxatives or lavage is advised.  
The main differential diagnosis for DIOS is chronic constipation, which is also a complication of 
CF. The prevalence of constipation in patients with CF is high, estimated to be around 47% (65). 
This is significantly higher than rates in the general population which range from 2% to 27% 
(67). Constipation is defined as gradual faecal impaction of the total colon (66) helping to 
differentiate it from DIOS. Patients are screened for constipation and DIOS at clinic visits via 
history and abdominal examination.  
CF also affects ion transportation within the hepatobiliary system and can lead to gallstone 
formation and CF related liver disease (CFLD). Estimates for prevalence of CFLD differ, with 
studies ranging from 4.2% to 38% (68). Risk factors include: severe mutations (class I to III), male 
gender and history of meconium ileus. CFTR is present in the apical membrane of 
cholangiocytes and epithelial gallbladder cells. The absence or altered function of CFTR results 
12 
 
in altered chloride and bicarbonate transport creating an increased volume of viscous bile with 
reduced alkalinity. The viscous bile causes plugging, inflammation and fibrosis within the liver 
as well as predisposing to other hepatobiliary pathology including cholelithiasis. The most 
common pattern of hepatobiliary damage is focal biliary cirrhosis (69). CFLD can result in 
significant morbidity as it can lead to liver cirrhosis, the formation of oesophageal varices and 
in severe cases requires liver transplantation (68). 
1.6.5 Reproductive 
CF is one of few conditions where male infertility is expected. Azoospermia in males with CF 
was first described in the 1960s (70) and the cause, bilateral absent vas deferens, was identified 
soon after. Although there is normal sperm production, there is an inability to transport sperm 
and consequently males with CF are infertile. As with many of the complications of CF, as life 
expectancy has increased, this complication has become of greater significance. Between 95-
98% of men with CF have obstructive azoospermia (71), although fertility is preserved in those 
with the 3849+10kb C > T mutation. Despite the fact that the majority of men with CF are 
infertile, reproductive technologies are now available to allow for aspiration of sperm from the 
epididymis allowing men with CF to father biological children (72).  
CF does not cause any anatomical reproductive abnormalities in females. However, it may still 
impact on fertility. The CFTR is present in the cervix (73) and the absence or dysfunction of the 
CFTR in CF patients leads to thickened cervical mucus, which can inhibit passage of sperm 
through the cervical canal and even plug the cervical canal (74). However in spite of these 
changes, in healthy women with CF who have been able to maintain good nutrition and achieve 
normal ovulation and menstruation, there is little evidence that fertility is significantly affected 
(73).  
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1.6.6 Summary of clinical manifestations of CF 
The clinical manifestations of CF are highly varied, and each individual will have a unique set of 
CF related complications depending on their environmental and genetic risk factors. The 
common and severe complications of CF have been focussed on in this review, but it is far from 
inclusive. There are multiple other conditions associated with CF including: sinus pathology, 
nasal polyps, rectal prolapse and pseudo-Bartter syndrome. The clinical manifestations of CF 
are summarised in Figure 3. 
1.7 Diagnosing CF 
The introduction of a nationwide newborn screening programme to the UK in 2007 (Wales 
1996, Scotland 2003) has revolutionised CF diagnosis. For example, in 2017, according to the 
Figure 3 - A graphic to summarise the numerous, multisystem complications of CF. 
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UK CF registry, of the 214 newly diagnoses of CF, 172 of these were identified by newborn 
screening (34). Newborn screening for CF forms part of the heel-prick test performed on 
neonates at 5 to 7 days old although the screening alone does not provide a definitive diagnosis 
of CF. If newborn screening is positive, further testing including sweat testing and genetic 
testing are then required to confirm the diagnosis of CF (75).  
As with any screening test, CF screening has disadvantages. These include: false positives 
causing unnecessary anxiety for families and unnecessary tests; limited genetic testing to only 
the most common mutations; and CF screen positive patients with an inconclusive diagnosis (CF 
SPID). CF SPID patients are babies that initially screen positive upon newborn screening but on 
further investigation do not meet the criteria for CF. Either sweat testing is normal (<30 mmol/L) 
but they have two CTFR mutations, at least one of which must be of unclear phenotypical 
significance or they have an intermediate sweat test but one or zero CFTR mutations (76). The 
clinical significance of CF SPID is unclear.  However, although testing undeniably has some 
pitfalls, newborn screening allows for early diagnosis and this has undisputable benefits such as 
improved nutritional status (77). 
Although newborn screening is now responsible for identifying the majority of cases, testing 
based on symptomatology is still a key part in diagnosing those with CF who may have not been 
screened or may not have been picked up at screening. This may be for a variety of reasons 
including the specificity of the immunoreactive trypsinogen assay and the limited panel of 
mutations included in genetic screening (78). The National Institute for Health and Care 
Excellence (NICE) recommends sweat testing in children and young adults who present with 
clinical manifestations of CF or have a family history of CF, whilst genetic testing is 
recommended in in adults (75). 
Antenatal diagnosis of CF is also possible. Until recently the main methods for diagnosis CF 
antenatally were chorionic villus sampling and amniocentesis. Both tests are invasive and are 
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associated with an increased risk of miscarriage (79). However new, less invasive and lower risk 
technologies are becoming rapidly available, such as non-invasive prenatal testing (NIPT), which 
simply involves taking a maternal blood test (80). In the UK, NIPT is currently available privately 
but not on the National Health Service (NHS) in all areas. These new technologies may enable 
parents to make informed decisions with regards to their pregnancy without the risks 
associated with amniocentesis or chorionic villus sampling.  
1.8 Management of CF 
The management of CF is complex and involves regular input from a multi-disciplinary team 
(MDT) of experts in CF care, including respiratory doctors, CF specialist nurses, dieticians, 
physiotherapists and psychologists.  
1.8.1 Pulmonary management 
Rigorous monitoring and management of CF lung disease is key in providing good outcomes. 
Pulmonary monitoring forms an integral part of management. In children monitoring occurs at 
least every 8 weeks and consists of: assessing lung function via spirometry (if the child is old 
enough), measuring oxygen saturations, clinical assessment and taking microbiological samples 
(81). Detailed annual review is required and includes blood tests, chest X-rays and further 
microbiological testing along with full involvement of the CF MDT. 
Regular physiotherapy is an important cornerstone in maintaining good lung function in 
individuals with CF. A variety of techniques can be used depending on the age and needs of the 
individual but the essential purpose is to clear as many secretions as possible (82). In infants, 
chest percussion is performed by parents to help remove secretions, whereas in older children 
airway clearance devices are often used. Some airway clearance techniques do not require 
equipment and rely on different breathing techniques to help remove mucus, such as huffing 
and coughing. Other techniques require devices to aid mucus clearance, these include positive 
expiratory pressure (PEP) devices and oscillating PEP devices such as acapella. There is little 
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evidence to suggest either device is more effective than the other and as such choices in 
physiotherapy technique are a combination of expert physiotherapist input and individual 
needs and preferences (83).  
Mucoactive agents are helpful in CF. The first line option is usually rhDNase. This can be used 
alone or in combination with hypertonic saline, which is the second line treatment. These 
agents are taken before physiotherapy to make secretions less viscous and aid their clearance 
(81). 
Antibiotics are another key part of pulmonary management in CF. They have four main 
indications (84): 
1. Treatment of a pulmonary exacerbation. This is typically achieved using with oral or 
intravenous antibiotics (85).  
2. Oral prophylactic antibiotics, for example flucloxacillin to reduce infection with S. 
aureus. 
3. Eradication of new organisms, such as P. aeruginosa. This usually requires courses of 
nebulised antibiotics with or without oral or intravenous antibiotics (86).  
4. Nebulised antibiotics to suppress chronic infection such as P. aeruginosa. 
There is no universally agreed definition of a pulmonary exacerbation in CF (85) meaning that 
identification and treatment of exacerbations can differ between CF centres and between 
clinicians at the same centre (87,88). The European Consensus Group defines a pulmonary 
exacerbation as the clinical need for additional treatment as indicated by a recent change in 
clinical parameters, although these parameters are not agreed upon (89). Although defining 
pulmonary exacerbations remains a challenge, there is consensus that exacerbations should be 
treated promptly and aggressively to improve quality of life, prevent a decline in lung function 
and ultimately reduce morbidity and mortality. A huge variety of organisms can be responsible 
for pulmonary exacerbations including viruses, bacteria, non-tuberculous mycobacteria and 
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fungi. The route, choice and duration of antibiotic will vary depending on the microorganism 
and sensitivities identified on culture, microorganisms previously grown by the patient and local 
practice (85).  
In children, the current recommendation is for prophylactic antibiotics (typically flucloxacillin) 
to be used in order to reduce infection with S. aureus. However, although this has been shown 
to reduce the number of isolates of S. aureus in these patients, whether there is actually any 
clinical benefit in taking prophylactic antibiotics remains debatable (90). Further research is 
being conducted into the efficacy of anti-staphylococcal prophylaxis through the CF anti-
staphylococcal antibiotic prophylaxis trial (CF START). There are concerns that the use of these 
prophylactic antibiotics may make children isolate P. aeruginosa earlier (17).  
Eradication of new organisms also requires prompt and aggressive treatment particularly with 
organisms such as P. aeruginosa. As previously mentioned, inhaled antibiotics are typically used 
to achieve this, sometimes in combination with intravenous or oral antibiotics. There is no 
universal consensus on what the optimal management of early P. aeruginosa infection should 
be (91). Trials are also been undertaken into the best route of administration of antibiotics in 
early P. aeruginosa infection including the Trial of Optimal Therapy for Pseudomonas 
Eradication in CF (TORPEDO-CF) study (92). The current approach within the North West 
Midlands CF centre is a stepwise approach with nebulised colomycin for 3 months as the first 
line combined with either oral ciprofloxacin or intravenous antibiotics. Should this fail to 
eradicate the P. aeruginosa, this is followed by 4 weeks of tobramycin second line and 4 weeks 
of aztreonam third line (93).  
Chronic infection with P. aeruginosa can be defined using the Leeds criteria (94) detailed in 
Table 1.2. As with early infection with P. aeruginosa, there is no universally agreed approach to 
management (95). The CF Trust recommends nebulised colistin as first line management (96). 
Anti-pseudomonal antibiotics have been shown to slow decline in lung function and reduce 
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morbidity including number of hospital admissions in patients with chronic P. aeruginosa 
infection (96). 
Table 1.2 - The Leeds criteria, describing P. aeruginosa infections 
Chronic infection When more than 50% of months, when samples had been taken, were P. 
aeruginosa culture positive. 
Intermittent 
infection 
When 50% or less of months, when samples had been taken, were P. 
aeruginosa culture positive. 
Free of infection No growth of P. aeruginosa during the previous twelve months, having 
previously been P. aeruginosa culture positive. 
Never P. aeruginosa never cultured from sputum or cough swab. 
 
1.8.2 Nutritional management  
Nutritional management is key in CF care as poor growth and nutrition are associated with an 
increased morbidity and mortality (89,97). A high-fat, high-calorie diet is recommended 
alongside sufficient pancreatic enzyme replacement therapy in patients who are pancreatic 
insufficient. Growth should be monitored regularly and height or length, weight and, in infants, 
head circumference should be recorded at every clinic visit and regularly during inpatient stays 
(97). All CF patients should have access to a CF specialist dietician who can provide dietary 
advice and support (55).  
Pancreatic insufficiency is objectively identified by a variety of tests, most commonly faecal 
elastase. In individuals who are pancreatic insufficient, replacement therapy is required. The 
amount of enzyme supplementation required depends on several factors including: weight, age, 
diet and clinical symptoms. Specialist dieticians can advise patients on the correct amount of 
enzyme supplements to be taken. 
Alongside pancreatic enzyme replacement, fat soluble vitamins often require replacement in 
those who are pancreatic insufficient due to fat maldigestion and malabsorption. Vitamin levels 
are checked regularly to assess for insufficiency and many patients require supplements of 
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vitamins A, D, E and K. These vitamins play important roles in: vision, skin, immune systems, 
respiratory symptoms, bone strength, clotting and reduction of chronic inflammation (98). A 
new vitamin supplement, Paravit-CF, has recently been introduced as part of routine CF care. It 
contains vitamins A, D, E and K in one tablet, helping to reduce the treatment burden in patients 
with CF.  
Patients with CF are also at increased risk of hyponatraemia due to excess sodium loss. Infants 
are at particular risk due to low dietary intake and increased surface area to volume ratio. There 
is no consensus on routine sodium supplementation (99), as such each case should be assessed 
on an individual basis. Factors that may wish to be considered include: infants’ increased losses, 
illness increasing losses, hot temperatures and climate and any situations that may cause 
excessive losses such as exercise, foreign travel and occupational hazards.  
Patients may also become calcium, zinc or magnesium deficient, and this is usually identified on 
blood tests. They may require supplementation in certain cases, and this again is judged on an 
individual basis and in accordance with local guidelines.  
1.8.3 Screening for complications  
As previously discussed, CF has multiple complications including diabetes and liver disease. A 
key part of managing CF is monitoring for complications to identify them at the earliest possible 
stage and optimise their management and prognosis. One way in which this is achieved is 
through annual review. Annual reviews are a yearly assessment for every patient with CF and 
include blood tests, clinical assessments, psychological assessment, assessments from 
physiotherapists, CF specialist nurses, social workers and dieticians. Blood tests include: liver 
function to look for early signs of CFRLD and testing for CFRD from the age of 10 onwards 
alongside other blood tests which help look at pulmonary and nutritional issues. Annual reviews 
have been associated with increased parent satisfaction and increased testing for potential 
complications of CF (100).  
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1.8.4 Psychosocial management  
CF is an undeniable challenge to live with both for patients and their families as such a holistic 
approach to care is of vital importance. Clinical psychologists form an essential part of the CF 
MDT and their assessments and support are vital for families and patients struggling with 
CF(101).   
CF management can also involve liaison with social workers and schools to ensure optimal care 
and social support for patients.  
1.8.5 New treatments  
Increased understanding of genetics presents an opportunity for targeted therapies in CF. CFTR 
modulators, drugs that work by improving the function of the CFTR channel, have shown the 
most promise in treating CF. Ivacaftor was the first CF treatment directly targeted at correcting 
or partially correcting the defect in the CFTR. Ivacaftor is a CFTR potentiator – meaning it works 
by improving the function of CFTR channels. It is thought to do this by increasing the open 
probability of CFTR channels enabling increased ion transportation can occur (102). Ivacaftor 
has been shown to be effective in patients with G551D mutation in terms of both lung function 
and quality of life scoring, but unfortunately was not shown to be effective in those with 
Phe508del mutations (103).  
Lumacaftor has been the next advance in CF genetic medicine. Lumacaftor is a CFTR corrector 
and aims to correct the processing and trafficking of CFTR channels. In combination with 
ivacaftor it is effective in patients with Phe508del mutations and trials (104). However, 
combination therapy is currently not recommended by NICE. Lumacaftor and ivacaftor dual 
therapy is available in the US and Ireland. There is ongoing campaign around enabling access in 
the UK (105).  
However, there are promising breakthrough’s for individuals who are homozygous for 
Phe508del. Dual therapy with tezacaftor-ivacaftor has been shown to improve lung function 
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and reduce rates of pulmonary exacerbation (106). Triple therapy involves a combination of 
two CFTR correctors with the potentiator ivacaftor (105). Clinical trials of triple therapy VX-659–
Tezacaftor–Ivacaftor (32) and VX-445–Tezacaftor–Ivacaftor (33) are even more promising, 
showing greater increases in lung function for individuals who have one or two Phe508del 
mutations. 
Gene replacement therapies have also been explored as a potential treatment for CF. Unlike 
the gene specific therapies already discussed, gene replacement therapies aim to replace the 
faulty CF gene as opposed to improving the function of CFTR. Gene replacement therapies 
typically use viruses as a vector to try and incorporate healthy CF genes into the individual’s 
cells to replace the faulty CF genes. Although there has been some promise in mice models 
(107), transferring these principals to humans remains challenging (108) and the results of gene 
replacement therapy remain underwhelming.   
1.9 Prognosis  
An increased understanding of CF, multidisciplinary care and new treatments have meant CF is 
now very rarely a cause of childhood mortality. It is predicted that should life expectancy 
continue to rise as it has done in recent years, children born with CF in 2010 can be expected to 
live to approximately 56 years old (109). 
1.10 Summary 
CF is a clinically important, life-shortening, non-curable genetic disorder affecting over 10,000 
individuals in the UK. There are a wide variety of symptoms and complications associated with 
CF, but respiratory complications are the leading cause of morbidity and mortality. Respiratory 
complications occur as a result of repeated airway infections leading to inflammation and 
fibrosis. Surveillance for infection forms an important element of respiratory management in 
patients with CF and this will be discussed in chapter 2.  
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2.0 Respiratory Microbiology in CF 
2.1 Respiratory pathogens in CF 
One of the defining features of CF is recurrent respiratory infections which over time lead to 
progressive inflammation and destruction of lung parenchyma.  
Evidence suggests that infants affected by CF rapidly acquire infections following birth (110) 
although they may be asymptomatic. Even in infants, who may only be a few months old, there 
can already be radiological evidence of structural lung disease. Although initial infection may 
not be present at birth, studies have shown that CF lungs are abnormal from birth, with mucus 
plugging and increased inflammatory markers present in bronchoalveolar lavage fluid even in 
absence of identifiable infection (111). Infection in infants is associated with poor nutritional 
outcomes (74). 
The bacteria that cause infection in children with CF are distinct from those that cause infection 
in unaffected children. In children without chronic respiratory disease, bacteria are a rare cause 
of respiratory infection with viruses causing most infections. Respiratory syncytial virus and 
rhinovirus are the major causes of infection (112) with common bacteria including 
Streptococcus pneumoniae and Haemophilus influenzae (113). However, in children with CF, 
initial infection in infancy and childhood is often with Staphylococcus aureus and Haemophilus 
influenzae (114). Figure 4 (34) highlights the changes in bacterial infections with age in 
individuals with CF.   
Older children and teenagers with CF are at increased risk of developing infection with P. 
aeruginosa. This is potentially the most clinically significant infection associated with CF as it 
has been shown to decrease lung function and increase morbidity and mortality (115). As such, 
early infection with P. aeruginosa is treated aggressively with antibiotics in an attempt to 
prevent infection becoming chronic. Furthermore, the subtype of P. aeruginosa affects a 
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patient’s prognosis as mucoid strains cause a more significant deterioration in lung function as 
compared to non-mucoid strains (116).  
 
P. aeruginosa is particularly challenging to treat partly due to its inherent resistance to some 
antibiotics and partly due to its lifecycle which involves the formation of biofilms (117). Biofilms 
are extracellular matrices which hold colonies of bacteria together, which makes antibiotic 
penetration and treatment significantly more challenging. Initially when P. aeruginosa infects 
and attaches to the lung surface the bacteria are in planktonic form, the bacteria then divide 
and go through several phenotypical changes finally resulting in large mucoid colonies 
surrounded by biofilms.  
Figure 4 (26) - A graph to show prevalence of different respiratory pathogens in different age groups 
from all individuals on the CF registry in 2017. Reproduced with permission from the CF Trust. 
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Other significant pathogens commonly seen in children with CF include Burkholderia cepacia 
complex. Infection with Burkholderia is also associated with a decrease in lung function and 
increased mortality (118) but infection is less prevalent than with P. aeruginosa. 
Viral, fungal and nontuberculous mycobacterial infections are also common in children with CF 
(119).  
2.2 The lung Microbiome in CF 
Not all microbes in the lungs are pathogenic. The microbiome is defined as the “ecological 
community of commensal, symbiotic and pathogenic organisms that share our body space” 
(120). Extensive research into the gut microbiome and its relation to multiple diseases has been 
undertaken (121–123). However, research into the lung microbiome is much more recent and, 
until recently, it was taught by some that the lungs are a sterile environment (124). 
Understanding the lung microbiome has important implications, as the lung microbiome has 
been shown to be altered and less diverse in those with chronic lung disease (125). Determining 
whether changes in the lung microbiome are merely a marker of disease, or contribute to 
disease pathogenesis is important and may be a potential target for disease modifying 
treatments (124). 
New technology is allowing researchers to gain a better insight into the CF lung microbiome 
with increasing numbers of bacteria, including those that have not previously been identified in 
CF lungs, now being researched (126–129).  In one recent study, presence of anaerobes in the 
lung microbiome was positively associated with pancreatic sufficiency, better lung function and 
better nutrition (130) demonstrating that the lung microbiome may be a marker of disease 
progression in CF. However, some of these anaerobic bacteria are associated with increased 
antibiotic resistance and inflammation and so the lung microbiome may directly be contributing 
to disease pathogenesis (131).  
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There are now several different methods for analysing the lung microbiome (131) including 
DNA, RNA and culture based methods.   
2.3 Symptoms caused by respiratory infection 
One of the challenges in identifying and treating infections in children with CF is that they can 
present in a variety of ways. Children may be entirely asymptomatic; a recent study found that 
infants with CF are more likely to be asymptomatic with viral infections than infants without CF 
(132). Asymptomatic infections are challenging as firstly, unless routine samples are taken, they 
may not be identified and secondly as the child appears well acceptance and adherence to 
treatment may be poor. Preschool children are particularly likely to have infection in the 
absence of symptoms and signs (133).  
Although some children may present asymptomatically, there are key symptoms that children 
with exacerbations of CF may present with. Notable symptoms include but are not confined to: 
increased cough, increased sputum production, new crackles and a decline in weight percentile. 
Early treatment with antibiotics can help reduce these symptoms and minimise further 
complications (134). Other factors that may indicate a pulmonary exacerbation of CF include: 
new or increased haemoptysis, increased dyspnoea, malaise, fatigue or lethargy, sinus pain or 
tenderness, change in sinus discharge, decrease in pulmonary function by 10% or more from 
previously recorded function and radiographic changes (26). These factors may indicate the 
need for antibiotic treatment and some studies have suggested that presence of 4 or more 
symptoms may indicate requirement for parenteral antibiotics (135).  
2.4 Identifying Respiratory Infections in Patients with CF 
Due to the lung damage caused by infections in children with CF, identifying and treating 
infections as promptly as possible is key and surveillance cultures should be performed on a 
regular basis. In children respiratory samples are taken at every outpatient appointment, these 
typically occur every 2 months although may be more frequent in infants or symptomatic 
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children. Cough swabs (CS), cough plates (CP), sputum samples and bronchoalveolar lavage 
(BAL) are the core methods used to identify infection. Table 1.3 summarises some of the 
methods used for respiratory sampling.  
Table 1.3 - Methods used for respiratory sampling 
Sample Type Description 
BAL Fluid squirted into and collected from the lungs during bronchoscopy 
Sputum Spontaneously expectorated sputum sample 
Induced sputum Sputum obtained following administration of hypertonic saline and 
physiotherapy 
CS Swab is placed in the pharynx, without touching the mucosa, the child 
is asked to cough 
CP Agar plates held 5 to 6cm from the child’s mouth. The child is asked to 
cough on each plate 
 
2.4.1 BAL 
A spontaneously expectorated sputum sample is the optimal lower airway microbiology sample 
in CF. Unfortunately, a lot of children and adults with CF are unwilling or unable to expectorate 
sputum. The gold standard for identifying lower respiratory infections in non-expectorating CF 
patients is BAL (136). BAL involves squirting fluid directly into the lungs and recollecting this 
fluid during bronchoscopy. As such it is one of the best methods for identifying infections in the 
lower respiratory tract. However, the number of lobes sampled can affect whether all 
pathogens are identified on BAL (137). An additional benefit of performing BAL is that during 
bronchoscopy the lungs can be visualised to look for evidence of airway damage and mucus 
plugging, and biopsies can also be taken to look for evidence of structural lung changes (138). 
However, it would be impractical to perform bronchoscopy on a routine basis to identify all 
infections. Bronchoscopy requires administration of a general anaesthetic and such an invasive 
procedure is not warranted for routine surveillance cultures (139,140). Therefore current NICE 
and CF Trust guidelines recommend if a patient is unable to provide a sputum sample, they 
provide CS as their routine microbiology surveillance sample (101,141).  
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2.4.2 Sputum 
A spontaneously expectorated sputum sample is the optimal lower airway microbiology sample 
for routine samples in CF and in adults and older children who are able to expectorate, 
monitoring for respiratory infections involves regular sputum samples. Sputum has a high yield 
for identifying pathogens and a high concordance with BAL samples (142) and is considered the 
gold standard for surveillance cultures in expectorating patients. 
2.4.3 Induced Sputum 
For children who are not able to expectorate, it is sometimes possible to induce sputum. The 
recent CF sputum induction trial (CF-SpIT) found that sputum induction, which involves giving 
hypertonic saline via nebuliser and physiotherapy to help the child produce sputum, was 
superior to CS at identifying pathogens (143). Induced sputum also identified 77% of the 
pathogens identified on two-lobe BAL. Consequently, one of the recommendations in this study 
was that induced sputum could be considered as an alternative to invasive bronchoscopy in 
symptomatic children.  
Although induced sputum is an important method for identifying infection in non-expectorating 
children, it is costly and time consuming in comparison to both CS and CP. Therefore, it would 
not be an appropriate method for sampling for routine surveillance at every outpatient 
appointment. Another disadvantage is that it is not always successful – 84% of procedures were 
successful in the CF-SpIT trial (143). However, the CF-SpIT trial has highlighted that sputum 
induction is a useful method for identifying infections in symptomatic children who are unable 
to expectorate. 
2.4.4 CS 
CS are the method of choice in almost all CF centres in the UK for children who are unable to 
expectorate. CS involve placing a swab in the pharynx, which is then cultured onto agar plates. 
They are quick, cheap and can be performed on children of any age.  
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However, CS have a significantly lower yield for identifying pathogens compared to sputum 
samples (144,145). As such, research into improving microbiological surveillance in young 
children with CF who are unable to expectorate is important. Positive CS are highly indicative 
of positive sputum cultures. However a negative CS, especially in the presence of symptoms, 
does not rule out infection (145).  
2.4.5 CP 
CP were first used as an alternative to CS in a study by Maiya et al. (2004) at Birmingham 
Children’s Hospital (146). As with CS, they are comparatively cheap and quick to perform in 
comparison to other sampling methodologies. They cannot be performed on young children as 
they require the ability to cough on demand. However, one advantage of CP is that they are 
preferred to CS by the majority of patients (146,147). 
CP have not been introduced at most CF centres as the evidence supporting their benefit in 
comparison to CS is conflicting (146–149). The evidence basis behind using CS and CP will be 
critically evaluated in the next section.  
2.5 CS versus CP 
There is debate as to whether CP are more effective at identifying infection compared to CS. A 
study into the relative efficacies of CS versus CP was performed by Maiya et al. (2004) and found 
the yield of pathogens identified on CP was significantly higher than from CS. In this study, 31 
patients participated and had sputum, CP, moist and dry CS taken. Twenty positive sputum 
cultures identified pathogens, with sixteen positive CP and seven positive moist and dry CS 
(146).  
However, as this study was performed in children who were able to expectorate, sputum would 
be the microbiological method of choice in these children. This brings into question the clinical 
relevance of this study and whether these results are applicable to non-expectorating children. 
A follow-on abstract was published by the team at Birmingham Children’s Hospital, 130 
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children, only 17 of whom could expectorate were included and similar results were found 
(150).The number of samples taken in the original Maiya et al. study is also small and so these 
findings may not be generalisable but having similar findings in the larger population in the 
follow on abstract increases the generalisability of these results.  
Increased identification of pathogens by CP has not been replicated in similar studies. A study 
of 95 subjects by Byrne et al. in 2013  found that pathogens were isolated on 18.2% of CS but 
only 8% of CP (147). This study did acknowledge there were benefits to CP as firstly, older 
children tended to isolate more specimens on CP – potentially due to a stronger cough 
mechanism and secondly, the majority of children preferred CP to CS.  
Two other studies by Chavasse et al. (2007) and Orska et al. (2006) had similar findings (148,149) 
with CS identifying a higher number of pathogens in comparison to CP. The lack of clarity 
regarding the efficacy of CP means they are rarely used in clinical practice in most CF centres. 
2.6 Non-culture-based techniques for identifying pathogens in CF 
Regardless of which of the above methods for respiratory sampling is used, they are usually 
then cultured in the lab to grow pathogens. However, new non-cultured based techniques are 
revolutionising the identification of pathogens in children with CF. Polymerase chain reaction 
(PCR), has the potential to identify more pathogens, more accurately than culture-based 
techniques (151).  
Use of molecular techniques such as PCR are especially relevant for clinically important 
pathogens such as P. aeruginosa, where PCR assays have been shown to have high sensitivity 
and specificity for identification (152). PCR is also beneficial for identifying bacteria that are 
not routinely identified by culture (151) which may be the cause of unexplained symptoms 
and failure to respond to treatment in children who appear to be growing no pathogens using 
culture based techniques.  
30 
 
2.7 Summary 
The gold standard for routine microbiological surveillance is sputum cultures. However, many 
children are unwilling or unable to expectorate sputum. CS have traditionally been used for 
surveillance cultures in non-expectorating children, but they have a low sensitivity. Alternative 
methods such as CP have been examined but the results of clinical studies are conflicting. 
Consequently, collection of routine microbiological samples from non-expectorating children 
with CF remains a challenge without a clear solution. 
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3.0 Aims and Objectives 
3.1 Introduction 
There is conflicting evidence regarding whether CS or CP are superior at identifying pathogens 
for routine surveillance cultures in non-expectorating children with CF. This indicates the need 
for further research in this area. 
Children with CF at Shrewsbury and Telford Hospital NHS Trust (SaTH) routinely perform CS and 
CP at each outpatient appointment and have done so for many years. There is a wealth of 
previously unused data at SaTH, including paired CS and CP results from children aged 2 to 18: 
potentially one of the largest collections of data regarding CS and CP use in the UK. This has the 
potential to answer important questions regarding the use of CS and CP including: does using 
both CS and CP increase detection of pathogens and do CS or CP identify important pathogens 
such as P. aeruginosa earlier. 
This study utilises 5 years of retrospective data to evaluate the performance of CP in comparison 
to CS.  
3.2 Aims and Objectives 
The principle aim of this thesis is to compare the performance of CS and CP at identifying 
respiratory pathogens in non-expectorating children with CF. The specific objectives are: 
Objective 1 
To collate paired microbiological results for CS and CP performed on children with CF at SaTH 
between November 2013 to November 2018. 
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Objective 2 
Collect relevant data at the time of these samples including: age of child, gender, lung function 
(percentage forced expiratory volume in 1 second -%FEV1) and weight, height and body mass 
index (BMI) centiles.  
Objective 3 
Attempt to detect a difference in pathogen yield between CS and CP.  
Objective 4 
To determine if age, weight, height, BMI centile or lung function affected performance of CS or 
CP.  
Objective 5 
To investigate if different organisms were more likely to be identified on CS or CP.  
Objective 6  
To investigate whether CS or CP were superior in aiding the early identification of P. aeruginosa 
in young children under the age of 7.  
3.3 Summary 
Further research into the comparative efficacy of CS and CP in non-expectorating children with 
CF is required due to divergence in previous studies. This study aims to compare these two 
methods used for surveillance cultures as well as answering other clinically important questions 
such as which method is superior at identifying early cases of P. aeruginosa. 
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4.0 Study Methodology 
4.1 Introduction  
This project comprised of three components: literature review, clinical experience of CF and 
microbiology, and data collection and analysis.  
4.2 Literature Review 
To gain an understanding of CF and respiratory microbiology a review of literature was 
undertaken. The review was non-systematic in its approach; however, I attended several 
lectures and workshops on systematic reviews at Keele University to gain an understanding of 
searching databases and critically appraising literature. Core medical databases including 
PubMed and Medline were searched for relevant literature. In addition, key articles were 
suggested by the project supervisor. Other important sources of information included Google 
Scholar, the Cystic Fibrosis Trust and the NICE for relevant clinical guidelines.  
4.3 Clinical Background and Relevance  
In order to appreciate the clinical relevance of this study, I attended the paediatric CF clinic at 
Royal Stoke University Hospital (RSUH) on a weekly basis for a year in order to gain a greater 
understanding of the disease and the multidisciplinary approach required to manage CF. One 
clinic was also attended at SaTH to observe paired cough swab and cough plate sampling being 
performed.  
A week’s observation was undertaken within the microbiology department at RSUH to gain an 
understanding of how respiratory samples are processed, pathogens are identified, and 
antibiotic sensitivities are determined. This was done at RSUH, as this was my base site and the 
site of both my supervisor and co-supervisor. However, as this experience did not happen at 
SaTH I did not have the opportunity to observe the processing of CP samples.  
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Time was spent in the containment level 3 laboratory to observe sputum samples and CS being 
inoculated onto agar plates. Plate reading and reporting was observed in the containment level 
2 laboratory, to gain an understanding of how pathogens are identified on plates and which 
pathogens can be identified on different media. An important learning point from this was that 
the majority of samples from patients with CF will grow bacteria and to a novice it can be 
difficult to differentiate between normal respiratory flora and pathogens. Another important 
lesson was that in vitro results are not always representative of the microbiology and 
sensitivities in vivo. 
Table 4.1 - The media used for CF respiratory samples at RSUH and the pathogens targeted by this 
media 
Media Pathogen targeted 
Chocolate Agar H. influenzae, M. catarrhalis, S. aureus  
Blood Agar S. pneumoniae 
CLED Enterobacteriaceae, Pseudomonads  
SAID S. Aureus 
Sabouraud Agar  Fungi 
B. cepacia selective agar B. cepacia complex 
  
During the week in microbiology time was also spent observing antibiotic sensitivity testing, 
helping to stain slides for mycobacterium and visiting the virology laboratories to gain an 
understanding of how viral samples are tested.  
4.4 Methodology for collecting CS and CP at SaTH 
CP and CS are performed routinely at every outpatient appointment for children with CF, which 
typically occur every 2 months although can be more or less frequent. CP and CS are taken by 
one of the CF team (specialist nurse, doctor or physiotherapist).  CP involve a series of 4 CP 
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being held approximately 5cm from the child's mouth. The child is then asked to cough twice 
forcefully on each plate. The 4 plates used at SaTH are: blood agar, chocolate agar, salt agar and 
Burkholderia cepacia selective agar. The plates are then sent for culture and read at 24 and 48 
hours. 
 
CS are performed using the standard methodology used at all CF centres, a swab is held in the 
pharynx and the child is asked to cough. The swab is then sent to the lab where it is cultured 
onto agar plates. At SaTH CS are cultured onto 6 plates: blood agar, chocolate agar, salt agar, 
Burkgolderia cepacia selective agar, CLED agar and a SAB+CHLOR (SABC) plate. The plates used 
and their costs are summarised in Table 4.2.  
 
Table 4.2 – The plates used to culture pathogens at SaTH and their costs.  
Plate CS or CP Cost of plate (pence per plate) 
Blood agar Both 18 
Chocolate agar Both 28.4 
Burkholderia cepacia 
Selective Medium 
Both 54 
Salt agar Both 24 
CLED agar CS only 17 
SAB + CHLOR (SABC) plate CS only 20.4 
 
The costs of performing CS alone are £1.62 per child with CP costing an additional £1.24, 
although this does not take into account the cost of clinics and analysis of samples. CS and CP 
are not performed in any set order in clinic and the order will often be the result of patient 
preference.  
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Although the addition of CP means patients are required to provide more samples and this can 
add to the length of clinic visits, the use of CS and CP appears to be well accepted by children, 
their families and staff at SaTH. Despite having to cough a total of 9 times for samples, the team 
at SaTH have had no complaints from families or children about the use of CP. 
4.5 Study Design and Population 
The study design was a retrospective review of paired CS and CP microbiological results for 
children with CF attending outpatient appointments at SaTH. Performing CS and CP on all non-
expectorating children who are old enough to perform CP has been standard practice at SaTH 
for over a decade.  
All paediatric CF patients who attended outpatient appointments with CF team at SaTH 
between November 1st 2013 to November 1st 2018 were included. They were identified by the 
SaTH Paediatric CF team providing a list of all their patients during this time. Only patients who 
were able to perform both CS and CP were included. This meant that children under the age of 
two were excluded. Patients capable of expectoration were not necessarily excluded. Although 
they may be productive at some appointments, this may not always be the case. Therefore, 
each appointment was checked to determine whether that patient had produced a sputum 
sample or whether paired CS and CP had been required.  
4.6 Data Collection 
4.6.1 Clinical Appointment Data 
Dates for outpatient appointments were collected from the outpatient appointment diaries and 
cross-checked against patient notes or clinic letters on the SaTH online system “Clinical Portal”. 
Occasionally, additional appointments were found in the notes or in clinical letters, which were 
not in the appointment’s diary. Using the diary, patient notes and clinical letters reduced the 
chance of missing any outpatient appointments. However, as this study is retrospective and 
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relied on hand written or typed records, there is a possibility that a small number of 
appointments may have been missed.  
4.6.2 Microbiology Results 
Once appointment details were collected, the results system “Review” was checked for CS and 
CP results collected on that day. As occasionally samples were not processed immediately, 
samples labelled as coming from the Paediatric Outpatient Department within 2 days of the 
clinic appointment were included. Only data for finalised reports of paired CS and CP was 
collected. If the report was interim and not finalised it was excluded. If there was only CS, 
sputum or CP performed the data was excluded.  
For a small number of children, two samples with different sample numbers were sent to the 
lab however, both samples were reported as CS or CP. Although it would appear that both a CS 
and CP had been taken in these children, both samples had to be excluded as it would be 
impossible to determine which result was from the CS and which result was from the CP.  
A small number of samples were collected in patients over the age of 18 as they were 
transitioning from paediatric to adult services. These samples were excluded for this study as it 
focuses on the paediatric CF population. Inclusion and exclusion criteria for samples are 
summarised in Table 4.3. 
Table 4.3 - Inclusion and exclusion criteria for microbiological samples 
Inclusion Criteria for Samples Exclusion Criteria for Samples 
CS and CP from Paediatric Outpatient 
Department processed within 2 days of 
outpatient appointment 
 
Final microbiological report 
Unpaired samples i.e. just cough swab, plate 
or sputum or sputum with only CS or CP 
 
Two samples both reported as CS or CP 
 
Interim report with no final report available 
 
Patient 18 years or older 
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Initially only one year of data was collected (November 1st 2017 to November 1st 2018) to assess 
the number of patients, paired samples and pathogens identified. However, following 
discussion with the statistics team at RSUH in the Research and Development (R&D) 
Department, it was recommended that five years’ worth of data would be required to have 
enough samples which grew pathogens to be able to perform significant statistical analysis. 
Power calculations were not performed, however they were performed for Byrne et al.’s study, 
which stated a sample size of approximately 400 was needed to provide 80% power to detect 
an effect size of 20% for growth of pathogens at the 0.05 significance level, taking into account 
repeated measures (147). 
4.6.3 Lung function and BMI data 
Alongside collecting microbiological results, data on lung function (% FEV1), height and weight 
were collected. These were initially collected from either the notes or from electronic clinic 
letters. Clinic letters were used for patients whose notes weren’t readily available as for 
example they had died, moved out of the area or transitioned to adult services. For any missing 
spirometry data, the spirometry software at SaTH, “Spirotrac”, was used to find missing results. 
For some of the younger patients, spirometry results were not available as although they were 
old enough to perform CS and CP samples, they were not old enough to perform spirometry. 
Whilst collecting the data on height, weight and lung function, the microbiology results were 
rechecked. This was done in order to minimise the chance of human error when collecting large 
volumes of data.  
Following collection of all the results, height, weight and BMI centiles were calculated from the 
recorded measurements. To calculate the centiles, the “Growth Charts UK-WHO” application 
was used.  
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4.7 Information Governance 
All data collected were recorded anonymously and stored on an encrypted memory stick. All 
patients were given a unique study identification number enabling data to be collected 
anonymously. Access to data was enabled by the team at SaTH who provided access to paper 
notes and information technology (IT).  
4.8 Incomplete data 
Due to the retrospective nature of this project, data were missing for some variables. Gender, 
age and microbiological results were collected for all 663 paired samples. However, data for 
BMI centile and lung function was not always available. 73 of the 663 samples (11%) did not 
have height and weight recorded to enable calculation of BMI centile. With regards to lung 
function, for 133 of the samples (20%) the child was too young to perform lung function. For 
the remaining 530 samples, where the child was old enough to perform lung function testing, 
26 samples were missing lung function data. 2 lung function samples were also removed as 
outliers, leaving a total of 502 samples for lung function.  
4.9 Cleaning Data 
Once data was collected, all variables were checked for outlying results. Outliers were defined 
as any result that was significantly higher or lower than other results for the same variable in 
that patient and did not follow the general trend of that patients results. Only 2 outliers were 
identified, which were low percentage FEV1s. These were both in young children who may have 
struggled with the techniques required to perform spirometry, it is possible these could be 
explained by exacerbations but is unlikely given how low these percentages were and the age 
of the children. These results were removed before data analysis.  
Microbiological results positive for non-pathogenic organisms: yeast, Candida albicans and 
bacillus species were also removed from the data-set. This was done on advice from the project 
supervisor, an experienced CF clinician, and considering relevant literature which highlights that 
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in the majority of cases these organisms are non-pathogenic (153,154), although there is some 
controversy around the role of C. albicans in CF (155). Bacillus species was labelled as a likely 
contaminant on the microbiological results and hence was removed from data analysis. 14 
paired samples identified non-pathogenic organisms alone, and 5 paired samples identified 
both non-pathogenic and pathogenic organisms. Of the 19 non-pathogenic organisms 
identified, 17 were cultured from CS. 
4.10 Statistical analysis 
In preparation for data analysis, I attended a module on statistics and epidemiology at Keele 
University to gain an understanding of commonly used study methodologies, statistical tests 
and their interpretation. Although not all of the statistical tests used in this study were covered, 
this module gave insight and competency in basic statistics.  
Appropriate statistical tests to meet the study aims and objectives were identified with help 
from the project supervisor, co-supervisor and the R&D department at RSUH. These tests 
include: number needed to sample (NNS), McNemar’s test, the generalised estimating equation 
and multivariable logistic regression. Simple tests including descriptive statistics and NNS were 
carried out using Microsoft Excel. Other statistical tests were carried out using STATA version 8 
(STATA Corp, Texas, USA). 
4.9.1 Number needed to sample 
In most CF centres in the UK, CS alone are used as the routine method for respiratory sampling 
for non-expectorating children. Therefore, one important component of this study was to 
compare whether taking paired CS and CP samples could improve identification of pathogens. 
The NNS is one method for estimating how many more children would require paired CS and 
CP compared to CS alone to identify one additional pathogen. 
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NNS was determined by first calculating the absolute risk reduction (ARR) using the formula 
𝑎
𝑎+𝑏
−
𝑐
𝑐+𝑑
  (see Table 3.4). The ARR was divided by 1 to calculate the NNS. 
Table 4.4 - How NNS is calculated 
 Positive  Negative 
Test 1  a b 
Test 2  c d 
 
4.9.2 McNemar’s Test 
Previous studies that have compared the results of CS and CP cultures have used McNemar’s 
test to determine whether there is  a statistically significant difference between CS and CP 
performance (146,147). 
McNemar’s test is a non-parametric test and is used with paired measures dichotomous data 
(156). It is used to compare proportions, and specifically uses discordant pairs (in this case a 
negative CS and positive CP and vice versa) to determine whether there is a significant 
difference in proportions. To perform the McNemar test data is converted into a 2x2 
contingency table as shown in Table 4.5, the formula 𝜒2 =
(𝑏−𝑐)2
𝑏+𝑐
 is then used to calculate chi 
squared test statistic and p value.  
Table 4.5 - How the McNemar test is calculated 
 Test 2 Positive Test 2 Negative 
Test 1 Positive a b 
Test 1 Negative c d 
 
This test is appropriate for this study as the groups are repeated, the same children had CS and 
CP performed, and the data is dichotomous, the CS and CP were either positive or negative. As 
this test was used in previous comparisons of CS and CP it also allows us to compare our results 
easily with previous studies. The null hypothesis in this study is the proportion of pathogens 
identified by CS is equal to the proportion of pathogens identified by CP.  
42 
 
However, application of McNemar’s test on this data set provides complications. The most 
important reason McNemar’s test is not optimal for analysis of the results in this study is the 
test does not adjust for the multiple paired measures we have from each patient. This is 
problematic as if one patient identifies more pathogens on CS or CP this could skew the results. 
This was not a concern in some previous studies, such as Maiya et al.(2004),  as each patient 
only gave one set of samples (146). However, in Byrne at al.’s (2013) study, 4 repeated sets of 
paired samples were taken from patients (147). McNemar’s test was performed separately on 
the first, second, third and fourth paired samples from each patient and an overall McNemar’s 
test using all samples was performed. It is unclear how multiple paired samples were accounted 
for in the overall McNemar’s test using all samples. For this reason, McNemar’s test was also 
calculated taking just one sample from each patient from the first to tenth sample in this data 
set.  
One potential solution is to use an adjustment for McNemar’s test that accounts for repeated 
measures (157). The statistics required for this are complex and beyond the scope of this thesis. 
However, we have contacted a clinical statistician to advise on this methodology before 
considering this work for publication elsewhere. 
4.9.3 Multivariable logistic regression 
The second aim of the data analysis was to identify whether age, BMI centile, gender and 
percentage FEV1 affected CS or CP positivity. In order to determine this, multivariable logistic 
regressions were performed for all variables for CS and CP separately. This analysis was 
suggested by the project supervisor, and basic information regarding logistic regressions was 
taught at the statistics and epidemiology course I attended. 
Logistic regression is a predictive analysis and is used to explain the relationship between one 
or more independent variables and a dichotomous or binary dependent variable. Logistic 
regression was used on this data set as the dependent outcome is binary – the CS or CP was 
43 
 
either positive or negative for a pathogen. Multivariable analysis was performed as it enables 
multiple variables to be analysed simultaneously and minimises the effects of confounding 
(158). All 663 CS and CP samples were input with the corresponding data for BMI centile, age, 
gender and percentage FEV1.   
However, as with McNemar’s test, repeated measures from patients are again problematic and 
mean results from the logistic regression should be interpreted cautiously. Logistic regression 
has been used in other studies, such as CF-SpIT, to assess the relationship between independent 
variables such as age and the likelihood of a positive sample (143). 
4.9.4 Generalised Estimating Equation 
Due to the issues surrounding multiple measures from patients, the generalised estimating 
equation was proposed as an alternative method for comparing CS and CP positivity and to 
overcome the limitations of logistic regression. This method does account for multiple 
measures but does not provide an easy comparison to previous studies. The generalised 
estimating equation was proposed as an alternative method of analysis by the project co-
supervisor. I then researched generalised estimating equations to gain a basic understanding of 
their applications to the analysis of longitudinal data.  
The generalised estimating equation is a statistical approach used in the analysis of longitudinal 
data  and can be used where there are repeated measures from the same individual or from 
related individuals, for example family members or people in the same geographical area (159). 
The generalised estimating equation was used in analysis of the results from the CF-SpIT trial to 
overcome issues with repeated measures (143). Although this study did not include CP, the 
study was comparing the use of CS to induced sputum and induced sputum with BAL. Therefore, 
as the statistical questions being asked were similar to the questions I was aiming to answer, a 
generalised estimating equation appeared to be the most appropriate method for addressing 
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the issues surrounding repeated measures in both the McNemar test and multivariable logistic 
regressions. 
Further work with statistician support will also be performed to identify whether the 
generalised estimating equation is the most appropriate method for analysis or whether 
another method is available which can account for the repeated measures from patients, before 
this research is published elsewhere.  
4.9.5 Organisms identified on CS and CP 
An additional aim of statistical analysis was to compare the types of pathogen identified on CS 
and CP. The number of times each different pathogen was isolated on CS and CP samples were 
collated and compared.  
For these more rarely isolated organisms, it was important to determine whether they are 
pathogenic or commensal as non-pathogenic organisms were excluded from analysis. There 
were 8 organisms only cultured a maximum of 4 times. These were: Streptococcus pneumoniae, 
coliform organisms, Enterobacter cloacae, Enterobacter asburiae, Moraxella catarrhalis, 
Acinetobacter pittii, Streptococcus pyogenes and Streptococcus dysgalactiae 
S. pneumoniae, M. catarrhalis and S. pyogenes are common documented causes of respiratory 
tract infection (160–162) and E. cloacae and E. asburiae are causes of nosocomial respiratory 
infection (163). Coliform organisms have been documented to cause pneumonia (164). 
 A. pittii has been reported as a cause of nosocomial respiratory infection (165) and 
Acinetobacter species have been cultured from CF patients (166). However in vitro studies have 
shown that A. pittii does not adhere to respiratory epithelium (167). Despite this as it has been 
shown to cause clinically relevant respiratory infections A. pittii was included.  
S. dysgalactiae has several subspecies and the specific subspecies is not known for these 
samples. S. dysgalactiae is a documented cause of respiratory infections and has similar 
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infective patterns to S. pyogenes (168). Therefore, all results were included in analysis, although 
it is possible some of these organisms may be non-pathogenic. 
4.9.6 Early detection of P. aeruginosa 
As discussed in Chapter 2, P.aeruginosa is one of the most clinically important pathogens in 
children with CF. It is a major cause of morbidity and mortality in children with CF, and early 
identification and treatment are one way to minimise the adverse outcomes associated with P. 
aeruginosa infection (169,170). P. aeruginosa is also being detected at increasingly younger 
ages, possibly as the result of advances in diagnostic techniques (171). As such it is important 
to see if the addition of CP aids in the identification of P.aeruginosa, particularly in young 
children. P.aeruginosa infections in children under the age of 7 in this cohort will be identified 
and will be analysed to see whether P.aeruginosa was identified by CS or CP and whether 
P.aeruginosa was identified again during the time period included in the study and by which 
sampling method.  
4.10 Ethical Considerations  
For this study, no official ethical approval was required, as according to the National Institute 
of Health Research (NIHR) this study is classified as service evaluation. Service evaluation 
defines or measures current practice within a service. As collection of both CS and CP samples 
in children with CF has been standard practice at SaTH for more than a decade, this project can 
be categorised as assessing this service. This was confirmed by the author and project 
supervisor completing the Health Research Authority (HRA) tool questionnaire (172), which 
established this project does not classify as research (see Appendix A). Ethical approval was 
therefore not sought.  
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5.0 Results 
5.1 Introduction  
The results will be detailed in this section. The aims of the statistical analysis are to address the 
following three objectives: 
1. To determine whether there was a difference in pathogen yield in CS compared to CP.  
2. To investigate if age, weight, height, BMI centile or lung function affected the likelihood 
of CS or CP being positive.  
3. To investigate which organisms were more likely to be identified on CS or CP.  
4. To identify whether CS or CP were superior at identifying P. aeruginosa in children 
under the age of 7.  
5.2 Study population 
663 paired CS and CP samples were identified from 38 patients from November 2013 to 
November 2018. 21 were males and 17 were females. The characteristics of the patient sample 
are outlined in Table 5.1, any outliers were omitted.  
Table 5.1 Characteristics of study population 
Characteristic Range Median Mean Standard Deviation 
Age (years) 2.2 to 18.0  8.8 9.9 4.7 
BMI centile 1st to 98th 52 51.7 25.9 
Lung function (percentage FEV1) * 38% to 115% 80 79.1 15.0 
Number of paired samples per patient 1 to 34 20 17.4 10.0 
*Normally distributed variables  
 
5.3 Overview of microbiological results 
Of the 663 paired samples, the CS and/or the CP was positive for a respiratory pathogen on 118 
(18%) of the paired samples. 14 samples only grew non-pathogenic organisms: yeast, Candida 
albicans and Bacillus species. These samples were not counted as positive as the organisms are 
not clinically significant.  
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There were 66 (10%) positive CS and 87 (13%) positive CP samples, some of which grew multiple 
pathogens. For 35 of the paired samples both the CS and CP were positive from the same 
appointment, there were 31 occasions where the CS was positive, and the CP was negative and 
there were 52 occasions where the CP was positive and the CS was negative. Hence there only 
being 118 positive paired samples in spite of 66 positive CS and 87 positive CP.  
Only 27 (23%) of the paired samples with a positive culture identified the same pathogen(s) on 
both CS and CP. 
Although there were only 66 positive CS, as some samples grew multiple pathogens CS 
identified 75 pathogens. The 87 positive CP identified 92 pathogens. 
5.4 Number needed to sample 
In this sample, 13 children needed both CS and CP samples to identify one additional respiratory 
pathogen compared to CS alone, this was calculated using the values in Table 5.2.  
Table 5.2 - The NNS in this population when comparing CS alone to using both CS and CP, demonstrating 
that 13 children would require both CS and CP as compared to CS alone to identify one additional 
pathogen. 
 
ARR = 0.078 
NNS = 13 
 
5.6 Determining whether there is a significant difference between CS and CP 
yield 
Two statistical tests were used to evaluate the yield of CS compared to CP. These were: 
McNemar’s test and the generalised estimating equation.  
 Positive   Negative 
CP and CS 118  545  
CS 66  597 
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5.6.1 McNemar’s Test  
McNemar’s test, shown in Table 5.3, demonstrates that there was a significant difference in the 
proportion of pathogens identified on CP compared to CS (p=0.028).  
Table 5.3 - Contingency table used in the calculation of McNemar’s test using all 663 paired samples. 
 The p value of 0.028 demonstrates there is a statistically significant difference in the number of 
pathogens identified by CS and CP.  
 Cough Plate  
Cough Swab  Positive Negative 
Positive 35 31 
Negative 52 545 
Chi-Square= 5.31 
McNemar’s Significance Probability= 0.028 
 
One method to account for the multiple paired measures in this study was to take just the first 
sample from every patient and perform McNemar’s test on those samples, the results for this 
are detailed in Table 5.4. When only taking one sample from each patient, there was no 
significant difference between CS and CP positivity (p=1.00). This was repeated for the 2nd to 
10th samples from each patient and no significant difference between CS and CP positivity was 
identified (see Appendix B).  However, this method significantly reduces the power of this test, 
as the sample size is decreased from 663 to 38 for the first sample. Sample size continues to 
decrease with each subsequent test due to patients providing different numbers of samples 
over the study period.  
Table 5.4 - Contingency table used in the calculation of McNemar’s test taking only the first sample from 
each patient.  
The p value of 1.000 demonstrates that when taking just one sample from each patient the difference 
between identification of pathogens by CS and CP is not statistically significant. 
 Cough Plate  
Cough Swab  0 (negative) 1 (positive) 
0 (negative) 3 4 
1 (positive) 5 26 
Chi-Square= 0.11 
McNemar’s Significance Probability= 1.000 
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5.6.2 Generalised Estimating Equation   
To calculate the generalised estimating equation, all 663 CS were input and labelled 0 and all 
663 CP samples were labelled 1 for the variable CS or CP. All other variables (age, BMI centile, 
gender and percentage FEV1) were included. The patient identification number was used to 
account for the repeated samples from each patient. The results of this analysis are shown in 
Table 5.5.  
Table 5.5 - Generalised estimating equation for the variables: CS or CP, age, gender, BMI centile and 
percentage FEV1 in predicting pathogen growth. 
 CS were input as 0, CP were input as 1, the positive coefficient therefore indicates that CP were superior 
at identifying pathogens (p=0.020). The only other statistically significant variable was percentage FEV1 
(p=0.005). 
Variable Coefficient with 95% 
confidence interval 
Standard error P value 
CS or CP 0.046 (0.007 to 0.084) 0.020 0.020 
Age -0.006 (-0.016 to 0.004) 0.005 0.244 
BMI centile 0.000 (-0.002 to 0.001) 0.001 0.612 
Gender 0.022 (-0.067 to 0.111) 0.045 0.630 
Percentage FEV1 -0.003 (-0.005 -0.001) 0.001 0.005 
Unique ID 0.005 (0.000 to 0.010)  0.003 0.051 
Wald Chi (6) = 19.23 
The generalising estimating equation showed that only 2 variables were statistically significant, 
i.e. had a p value of <0.05 and a 95% confidence interval that does not cross zero. These 2 
variables were CS or CP (p=0.020) and percentage FEV1 (p=0.005).  
As CS were labelled as 0, and CP labelled as 1, the positive coefficient demonstrates that, 
according to this model, CP was associated with positive culture growth. The low coefficient of 
0.046 indicates that although the relationship is statistically significant, the magnitude of this 
relationship is small as CP are only associated with a 0.046 times increase in the likelihood of 
identifying a pathogen compared to CS. The coefficient of -0.003 for percentage FEV1, means 
that according to this model, a 1% increase in FEV1 is associated with a 0.003% decrease in the 
likelihood of a positive culture growth.  
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5.7 Determining whether age, BMI centile, gender and percentage FEV1 predict 
CS and CP positivity.  
The results of multivariable analysis for CS can be found in Table 5.6 and the results of analysis 
for CP can be found in Table 5.7.  
Table 5.6 - Multivariable analysis with odds ratio (OR) for variables: age, gender, BMI centile and 
percentage FEV1 predicting CS positivity. 
The only significant predictor of CS positivity was percentage FEV1 (p=0.017). 
 N= OR * Adjusted with 95% CI P value* 
Age 663 1.022 (0.936, 1.116) 0.627 
Gender 663 0.783 (0 .398, 1.538) 0.477 
BMI centile 590 1.002 (0.986, 1.018) 0.826 
Percentage 
FEV1 
502 0.969   0.017 
 
Table 5.7 - Multivariable analysis with odds ratio (OR) for variables: age, gender, BMI centile and 
percentage FEV1 predicting CP positivity.  
BMI centile (p=0.031) and percentage FEV1 (p=0.002) were the only statistically significant predictors of 
CP positivity.  
 N= OR * Adjusted with 95% CI P value* 
Age 663 1.066 (0.989, 1.148) 0.093 
Gender 663 1.192 (0.672, 2.113) 0.549 
BMI centile 590 1.015 (1.001, 1.030) 0.031 
Percentage 
FEV1 
502 0.964 (0.941, 0.987) 0.002 
*Adjusted for: age, gender, BMI centile and percentage FEV1 
For CS, the only statistically significant predictor of CS positivity (p<0.05) was percentage FEV1 
(p=0.017). FEV1 was associated with positive culture growth using both the generalised 
estimating equation and multivariable analysis. 
For CP, percentage FEV1 was also a statistically significant predictor of CP positivity in 
multivariable analysis (p=0.002). BMI centile also contributed to CP positivity (p=0.031).  
5.8 Identification of different organisms on CS and CP 
The final aim of data analysis was to compare the different types of organisms identified on CS 
and CP.  
51 
 
14 different pathogens were isolated from the CS and CP. Although CP identified a greater 
number of pathogens, a greater variety of pathogens were identified on CS. CS identified 6 
pathogens that were not identified on CP: Enterobacter. cloacae, Enterobacter. asburiae, 
Moraxella. catarrhalis, Acinetobacter. pittii, Streptococcus. pyogenes and Streptococcus. 
dysgalactiae. Some of these pathogens were cultured on multiple occasions resulting in 10 
growths that were not identified by CP. As one CS or CP could identify multiple pathogens, the 
total number of pathogens identified by each sampling method is greater than the total number 
of positive CS and CP. In total CP identified x pathogens and CS identified x pathogens. Figure 5 
summarises the pathogens identified by CS and CP and the number of times they were cultured. 
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Figure 5 – A graph to show pathogens identified by CS and CP samples. There were only 66 positive CS, 
as some samples grew multiple pathogens CS identified 75 pathogens of which there were 14 different 
types of pathogen. The 87 positive CP identified 92 pathogens. CP identified 8 types of pathogen. 
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5.9 Growth of P. aeruginosa in children under the age of 7 
Of the 38 children included in this study, only 4 children under the age of 7 grew P. aeruginosa 
during the study period on either CS or CP. In these 4 children the first growth of P. aeruginosa 
during the study period was from CP 2 times, CS 1 time and both CS and CP 1 time. In two cases, 
P. aeruginosa was grown again during the study period and in both these cases the second time 
P.aeruginosa was cultured it was from CS. Table 5.8 summarises these findings. 
Table 5.8 – Growth of P. aeruginosa in children under the age of 7.  
P. aeruginosa was isolated from four children during the study period, 2 times from CP once 
from CS and once from both. Two children grew P. aeruginosa again during the study period, 
both times from CS. 
Patient Age P. aeruginosa 
first isolated in 
study period 
(years) 
Method P. 
aeruginosa 
identified by 
Did P. 
aeruginosa 
grow again 
during study? 
Method second 
growth 
identified by 
Age at 
second 
growth 
(years) 
1 4.7 CP  No - - 
2 5.8 CS Yes, once CS 6.5 
3 6.3 CP No - - 
4 5.0 CS and CP Yes, once CS 6.3 
 
5.10 Summary  
663 paired samples were identified in data collection. CP were positive more frequently than 
CS (87 times compared to 66) but whether there is a significant difference between CS and CP 
performance is challenging to ascertain due to repeated measures. McNemar’s test and the 
generalised estimating equation would suggest that CP were statistically significantly more 
likely to identify pathogens. Although the comparison of CS and CP is important, a key finding 
from these results is that performing both CS and CP increased the yield of positive samples to 
18% compared to 10% when using CS alone. 
Percentage FEV1 was the only consistent predictor of CS and CP positivity when looking at the 
variables age, BMI centile, gender and percentage FEV1 in multivariable analysis. BMI was a 
significant predictor of CP positivity in multivariable analysis.  
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14 different organisms were isolated on CS and CP samples. CS identified a greater range of 
organisms including 6 organisms not identified on CP.  
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6.0 Discussion 
6.1 Introduction  
This chapter focuses on discussing the results of this service evaluation, in relation to current 
literature and the study aims, and considers the strengths and limitations of this study as well 
as recommendations for future research and clinical practice.  
6.2 Comparing CS and CP yield.  
The principal aim of this project was to compare the performance of CS and CP at identifying 
respiratory pathogens. 663 paired samples were analysed, and overall CP identified a greater 
yield of pathogens compared to CS (87 positive CP compared to 66 positive CS). 10% of CS were 
positive, this is lower than rates found in previous studies where between 13 and 26% of CS 
positively identified pathogens (145–147). 13% of CP were positive, this is consistent with 
findings in previous studies which have ranged between 8 and 52% (146,147).  
Past studies looking at the use of CS and CP have focussed on comparing the two sampling 
methodologies (146,147). However, one of the key findings is that the yield of CS was 10% 
compared to 18% when using both CS and CP. This demonstrates that the addition of CP could 
benefit many patients and clinicians by identifying a greater yield of pathogens.  
6.2.1 Comparison of results to previous literature  
6.2.1.1 CF-SpIT 
The CF-SpIT is one of the most recent trials to look at methods of identification of respiratory 
pathogens in non-expectorating children with CF (143). As one arm of this trial 167 paired CS 
and induced sputum results were collected. 14% of CS were positive for pathogens in this trial, 
which is higher than the yield found in this study.  
There are numerous differences between the study population included in the CF-SpIT 
compared to this service evaluation. Firstly, the age range of children included was larger in the 
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CF-SpIT as children could be recruited from 6 months to 18 years. Secondly, children would be 
recruited not just from outpatient appointments, as in this study, but children who were 
inpatients for exacerbations, having routine surgery under general anaesthetic or attending for 
clinically indicated bronchoscopy were also invited to participate. As inpatients who were 
acutely unwell were also included in the CF-SpIT, this may partially explain the higher rates of 
isolation on CS in this study as children with exacerbations are more likely to have infections 
and therefore positive samples. Finally, children who were on antibiotic treatment at the time 
of sampling were excluded from CF-SpIT and again this may partially explain the higher yield of 
positive CS.  
The key findings of CF-SpIT were that sputum induction was positive for pathogens significantly 
more often than CS (38% compared to 14%) and that sputum induction was positive a similar 
number of times compared to two-lobe BAL (69% of pathogens identified by sputum induction 
compared to 72% on two-lobe BAL). The key recommendations of this research were that 
performance of sputum induction in symptomatic children is beneficial and could reduce the 
need for BAL. These finding are very important but do not address the low sensitivity of CS as a 
routine sampling method at every outpatient appointment. Sputum induction could not be 
performed on every non-expectorating child at every clinic visit as it is time consuming, with 
the procedure taking up to half an hour in the CF-SpIT. Therefore although sputum induction is 
a useful method for pathogen identification in symptomatic children, it does not negate the 
need for research into alternative methods for routine surveillance cultures such as CP. 
6.2.1.2 CP versus CS in patients with CF; a pilot study (Maiya et al.) 
 Maiya et al. reported CS were positive 23% of the time and CP 52% of the time in their study 
on 31 children (146). These yields are both higher than those found in this service evaluation 
and there are several differences between the study populations which may account for this. 
The Maiya et al. study recruited older children aged 8 to 16 who were able to expectorate so 
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that the results could be compared to sputum. Older children are more likely to have chronic 
infections and reduced lung function and as such it is unsurprising that a higher yield of 
pathogens was identified.  
CS were also only inoculated onto 4 plates in this study. This does not explain why the yield is 
higher than in our service evaluation but may partially explain why there was such a marked 
difference between CS and CP yield.  
In spite of the differences in methodology and study population, the key findings of the Maiya 
et al. study do mirror the findings in this service evaluation as CP identified more pathogens 
than CS.  
6.2.1.3 The efficacy of CP in the identification of bacterial pathogens in children with CF 
(Byrne et al.) 
The study into the efficacy of CP by Byrne et al. is the study most discordant with our findings. 
Byrne et al. reported CS to have an 18.2% positivity and CP to have an 8% positivity with 
concordance in just 5.5% of samples (147).  There are some differences in the study population 
and methodology which may account for this. 
Firstly only 3 CP were used in this study, which could partially explain the lower yield of positive 
CP. However, CS were also only inoculated onto 3 agar plates, so this does not fully explain the 
higher yield of CS. 
Children over the age of 3 were recruited for the Byrne study, and so the study population age 
is most similar to this service evaluation. Only non-expectorating children were included in the 
Byrne study and it is not clear whether this means the child was unable to expectorate at that 
appointment or was never productive of sputum. In this service evaluation, whether a child was 
able to expectorate was judged at every appointment so children who were sometimes able to 
expectorate were included. This may partially explain some of the observed differences 
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between this service evaluation and Byrne et al.’s study, but it is unclear why the difference in 
results is so marked.   
6.2.2 Number needed to sample 
Current clinical practice in the majority of CF centres is for non-expectorating children to 
perform CS alone at every outpatient appointment. By taking paired CS and CP samples, the 
NNS was 13, meaning that for every 13 children to have paired CS and CP samples taken, one 
additional pathogen is identified compared to CS alone. This further suggests that by taking 
duplicate samples identification of pathogens may be improved.  
6.2.3 McNemar’s Test 
While difficult to ascertain, the difference between CS and CP yield is statistically significant. 
The McNemar test has been used in previous studies to compare CS and CP performance 
(146,147) but poses problems in this study due to the inclusion of repeated paired CS and CP 
samples from each patient. When McNemar’s test was performed on all samples, it suggested 
there was a statistically significant difference between CS and CP (p=0.028). However, when 
one sample was taken from each patient, from the first paired sample provided during the study 
period to the tenth paired sample provided, none of the results demonstrated a statistically 
significant difference. This illustrates that an unadjusted McNemar’s test may not be a reliable 
method for determining whether there is a statistically significant difference in CS and CP 
positivity when there are multiple paired measures from each patient and is the major reason 
why McNemar’s test is not the optimal statistical test for analysis of these data.  
Similar findings were seen in a study undertaken by Byrne et al. (2013) where patients had 
paired CS and CP samples taken at four different clinic visits. For three out of the four clinic visits 
there was no statistically significant difference between CS and CP (147).  
The McNemar test provides an additional challenge as the different organisms identified by CS 
and CP cannot easily be incorporated into the analysis. For example, a CS and CP sample from 
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the same appointment could both be positive for different organisms. The McNemar test 
dictates that this result would be considered the same as a CS and CP that were both positive 
for the same organism as the test only compares the binary variable of whether the CS or CP 
are each positive or negative. This may be a theoretical criticism, as only two of the 663 paired 
samples in this study identified different pathogens on CS and CP in the same appointment, and 
therefore were unlikely to significantly alter results. However, in one of these discordant cases, 
CP identified P. aeruginosa whereas CS identified H. influenzae. Although both clinically 
important, P. aeruginosa is the most important pathogen to identify and so counting these 
samples as the same does risk missing important information about the types of pathogen 
identified by CS and CP.  
Multiple pathogens growing from one CS or CP sample are also overlooked in this test. This 
makes interpretation more challenging. The McNemar test should therefore be interpreted 
cautiously both in this study but also in previous studies comparing CS and CP. 
6.2.4 Generalised estimating equation 
In addition to performing McNemar’s test, a generalised estimating equation was performed as 
an alternative method to establish whether using CS or CP was predictive of positive pathogen 
results. This was done as the generalised estimating equation accounts for repeated measures 
and can also adjust for additional variables: age, gender, BMI centile and percentage FEV1.  
The generalised estimating equation demonstrated that CP was a statistically significant 
predictor of positive results (p=0.020). For the purposes of the generalising estimating equation 
CP was defined as 1 and CS was defined as 0. The positive coefficient (0.046) demonstrates 
therefore that CP were predictive of pathogen positivity. 
Percentage FEV1 was also statistically significant (p=0.005) and had a negative coefficient (-
0.003). This demonstrates that the children in this study were more likely to have a positive 
result on CS or CP if they have reduced lung function.  
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The coefficient for both percentage FEV1 and CS or CP was low and therefore, although 
statistically significant, the clinical significance of these results remains unknown. Further 
exploration with statistician support will be required to investigate the predictive capacity of CS 
and CP in identifying pathogens.  
6.2.5 Sampling technique – is it fair to compare CS and CP? 
Another factor to consider when comparing CS and CP yield is the technique required to 
perform CS and CP. CS involve coughing once, occasionally twice, onto a swab held in the 
pharynx. CP involve the child coughing forcefully onto a plate held 5-6cm from their mouth. At 
SaTH, four CP are collected from each child. The observed difference between CS and CP may 
be the result of CS only requiring one cough and CP requiring eight coughs. By coughing more 
times, there is an increased likelihood of producing an adequate respiratory sample to identify 
pathogens from.  
It could be argued that the comparison between CS and CP is an unfair one to make as CP involve 
more coughs and therefore it is unsurprising more pathogens will be detected. Conversely, CS 
have the advantage of being cultured on to more agar plates and so perhaps it is unsurprising 
that in this study they identified a greater variety of pathogens. Ultimately if one method was 
intrinsically better than the other, it is unlikely that there would be the discordance of results 
seen in previous studies (146,147).  
To make the comparison between CS and CP fairer, one suggestion would be to ask children to 
cough onto four CS as well as four CP. However, this is unlikely to be acceptable for many 
children and more time consuming for staff. Although, this method may be an option for future 
research, it is highly unlikely that CF centres would be willing to adopt this for routine clinical 
practice.  
Another potential method for making the comparison between CS and CP fairer would be to 
have multiple types of agar on one plate. Research would need to be conducted to determine 
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whether multiple types of agar are still as effective at identifying pathogens, but this could 
potentially reduce the number of coughs required from children both for research purposes 
and in clinical practice.   
6.3 Predictors of CS and CP pathogen identification  
Lung function, indicated in this case by percentage FEV1, was the only significant predictor of 
both CS and CP positivity in multivariable analysis and analysis with the generalised estimating 
equation. As both multivariable logistic regression and the generalised estimating equation 
showed similar results, this increases the confidence that the relationship between lung 
function and positive CS or CP is a relevant finding.  
In multivariable regression, for both CS and CP the OR was less than 1, meaning an increased 
FEV1 is associated with a decreased likelihood in CS or CP identifying a pathogen. For CS the OR 
was 0.969 (95% CI 0.944, 0.994), for CP the OR was 0.964 (95% CI 0.941, 0.987), demonstrating 
that for both CS and CP and increase in FEV1 of 1% was associated with a 3-4% reduced likelihood 
of a positive CS or CP. This is perhaps an unsurprising finding as it is well established that 
respiratory infections are associated with reduced lung function even in infancy (84,114,173). 
Ultimately, children with poor lung function in CF are more likely to have an infection and 
therefore more likely to have a positive CS or CP.  
BMI centile was also a significant predictor of CP positivity (p=0.031). Surprisingly the odds ratio 
for this was 1.015 (95% CI 1.001, 1.030) suggesting an increase in BMI by 1% is associated with 
1.015 times greater odds of the CP being positive. This is surprising as it is well documented that 
reduced BMI is associated with poor respiratory outcomes (174,175). One potential explanation 
is that increased BMI may be associated with increased cough strength. Further research would 
be required to assess the relationship between BMI centile and CP and the relationship between 
BMI centile and cough strength.  Why this relationship was observed in CP and not CS is unclear.  
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It is important to note that as with the McNemar test, there are issues surrounding repeated 
measures from the same patient with regards to the multivariable logistic regression. However, 
as similar findings were shown in the generalised estimating equation, which does account for 
repeated measures, this increases the confidence that there is a statistically significant 
relationship between percentage FEV1 and positive CS or CP. The relationship between BMI 
centile and positive CP is less clear as BMI centile was not associated with a positive result when 
using the generalised estimating equation. It is also possible this may be a chance finding. 
The only other study to consider predictors of CS and CP positivity is Byrne et al. (2013) (147). 
Due to the low number of positive CP identified in this study, statistical analysis was not 
performed on predictive variables. However, Byrne describes a trend of older patients isolating 
more pathogens on CP and postulates this may be the result of increased cough strength. Given 
the findings in this study, the increased positivity of CP with age may be a consequence of 
declining lung function as patients age increases. Cough strength was not explored in this study 
and could still be an important variable in predicting whether pathogens are identified on CS or 
CP.  
Another variable not explored in this study or past studies is the technique required in 
performing CP. CS can be performed on all children regardless of age, as even if the child is 
unable to cough on demand, insertion of the swab into the pharynx often triggers a cough. CP 
are reliant on children being capable of generating a strong cough on command. Byrne’s 
observation of older children isolating more pathogens on CP, may be the result of them being 
able to produce adequate CP samples which may be more challenging in younger children.  
6.4 Types of pathogen identified on CS and CP.  
Non-pathogenic organisms were identified in greater numbers using CS. This finding is similar 
to that of Maiya et al. (2004), who also demonstrated that CS identified more non-pathogenic 
organisms compared to other respiratory sampling methods (146). One potential explanation 
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for this trend is that CS are more likely to be contaminated by pathogens as they may touch the 
oropharyngeal tissues when they are performed when compared to CP. 
The common and important organisms seen in patients with CF were identified more frequently 
by CP. Namely: P. aeruginosa, S. aureus and H. influenzae. A similar pattern was seen by Maiya 
et al. where CP identified more cases of P. aeruginosa than any other sampling method used. 
However, these findings have not been replicated in other studies and are discordant with 
findings from Byrne et al. (2013), Chavasse et al. (2007) and Orska et al. (2006) (147–149).  
Although CP identified a greater number of pathogens, a greater variety of pathogens were 
identified on CS. This may be because CS can be inoculated on to a wide variety of media 
whereas CP are limited to the number of plates the child has coughed on. At SaTH it is standard 
practice for CP to be performed on 4 plates: blood agar, chocolate agar, salt agar and cepacia 
specific agar, whereas CS can be plated onto 6 plates. 
It is also possible that some of the additional organisms identified on CS may be commensal 
organisms. Although there is evidence that some of the less frequently isolated organisms can 
be pathogenic, there is also evidence they may be commensal. When taking CS samples, there 
is a greater risk they may be contaminated as the swab is held in the pharynx. Although CS 
should not touch the oropharyngeal mucosa (176), the risk of this occurring is much greater 
than with CP as they are held approximately 5 centimetres from the child’s mouth.  
6.5 Identification of P. aeruginosa in children under the age of 7 
P. aeruginosa is arguably the most clinically significant pathogen in children with CF but early 
identification and treatment has the potential to reduce some of the adverse outcomes 
associated with P.aeruginosa infection. In this cohort of patients only 4 children under the age 
of 7 isolated P.aeruginosa. 2 of these cases were identified on CP, one on CS and one on both. 
It is possible that P.aeruginosa may have been isolated in these children before the study period 
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began, before they were old enough to perform both CS and CP or by other methods during the 
study period such as induced sputum or BAL.  
No strong conclusions about the benefit of the addition of CP for the early identification of P. 
aeruginosa can be drawn from just 4 patients. However, without CP 2 of these 4 cases could 
have been missed, this suggests that CP may aid with the early diagnosis of P. aeruginosa. CP 
also grew a greater number of P. aeruginosa isolates in the whole study population cohort 
compared to CS, CP grew P. aeruginosa 32 times, CS 24 times. If these findings could be 
replicated in a larger population of patients, this could have important ramifications for clinical 
practice as the early identification of P. aeruginosa is very important for children with CF.   
6.6 Study Strengths and Limitations 
Although this study addresses the aims and objectives set, it is not without limitations. Firstly, 
due to the retrospective nature of the study design it data were missing from records for some 
variables. Also, as a retrospective study there are limitations as to what variables we could 
explore in relation to CS and CP positivity such as cough strength. Important additional variables 
that would be useful to explore in future studies include: presence of bronchiectasis, whether 
the child was symptomatic or asymptomatic at the time the sample was taken, the genetics of 
the child and the antibiotic sensitivities of pathogens. 
Secondly, although this study has a large number of paired samples, the samples come from a 
relatively small population of 38 patients. Therefore, the findings of this service evaluation may 
not be generalisable to all children with CF.  
Another limitation of this study is that when comparing pathogen growth only a binary positive 
or negative growth was used. When microbiological results are reported they also describe the 
amount of pathogen grown: scanty, moderate or heavy growth. This detail was not included in 
our analysis and therefore details on the amount of growth when comparing CS and CP may 
have been missed.  
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Finally, these samples were only collected from an outpatient setting as inpatients with CF at 
SaTH do not routinely have CP performed as ward staff are not trained to take both CS and CP. 
Therefore, the results of this study may not be applicable to acutely unwell children who require 
admission. However, as discusses in chapter 2, induced sputum may be the optimal method for 
identifying pathogens in symptomatic non-expectorating children with CF (143).   
However, this study does have strengths when comparing it to other studies that have explored 
the use of CS and CP. Firstly it has the largest number of paired CS and CP samples explored in 
any of the past studies. 
 Secondly this is the first study to explore with statistical analysis whether age, gender, BMI 
centile and percentage FEV1 predict a positive CS or CP result and therefore provides novel 
insight into these variables.  
6.6 Recommendations for further research  
This service evaluation demonstrates that by taking multiple samples from each patient at every 
clinic visit, the yield of pathogens identified is increased. However, it is not currently clear if the 
increased identification is due to having taken both CS and CP samples or simply the result of 
having multiple samples. Therefore, further research is required to discern whether taking 
multiple CS or CP would also increase the identification of pathogens. Additionally, another 
avenue that could be researched is whether increasing the frequency of taking respiratory 
samples increases the identification of pathogens. 
Cost benefit analysis of performing both CS and CP samples is another potential area of future 
research. At SaTH CS alone cost £1.62, whereas performing both CS and CP costs £2.86. 
Although analysing the cost of additional CP samples is straightforward, determining whether 
any savings are made, such as through reduced need for induced sputum or BAL would be more 
challenging.  
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Finally, this study suggests that CP are statistically significantly more likely to identify pathogens. 
Due to the small number of participants in this study, it is important to determine whether 
these findings are generalisable to all children with CF. Therefore, comparison of CS and CP in a 
significantly larger study population is recommended. 
6.6.1 Future study proposal 
This service evaluation identifies several options for further research. However, the most 
important findings from this service evaluation are that by performing both CS and CP a greater 
yield of pathogens are identified, and that the addition of CP may be beneficial in the early 
identification of P. aeruginosa. Demonstrating these findings in a larger study population to 
ensure generalisability is the most pressing need for future research. 
Therefore, my ideal future study would be a study into the benefits of performing both CS and 
CP in a larger patient population. Ideally it would involve a larger CF centre or several CF centres 
from different geographical locations. Non-expectorating children old enough to perform CP 
would be invited to participate and CS and CP would be performed on these children at every 
clinic for a year. Although the comparison of CS and CP may not in itself be a fair comparison 
(as detailed in section 6.2.5) unless advances could be made in using multiple agars on one 
plate, it would be impractical and unfair to expect children to perform 4 CS and 4 CP, therefore 
I would use the same methodology for collection of CS and CP samples as outlined in this study.  
At the time of taking samples, data on the child’s lung function, age and BMI would be collected. 
It would also be important to have more background data on the child than was collected for 
this service evaluation including: whether the child was symptomatic or asymptomatic at that 
appointment, their genetics, whether they have any evidence of bronchiectasis and whether 
they have grown P. aeruginosa in the past or from BAL or induced sputum during the study 
period. This additional information would enable further analysis as to whether any of these 
variables predict CS or CP positivity. Importantly the information regarding P. aeruginosa would 
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enable stronger conclusions to be made about the benefits of CP in the identification of initial 
P. aeruginosa infection.  
Collecting samples over a year would provide challenges statistically due to repeated measures. 
However, the longitudinal data enables further analysis that would not be possible if only one 
sample was taken from each patient. For example, you could follow children up who grew P. 
aeruginosa by any of the sampling methods to see if they grew it again during the study period 
and whether CS or CP identified it. 
Instead of the focus of this study being a comparison between CS and CP, the aims of this study 
would be to identify whether by performing both CS and CP, more cases of P.aeruginosa are 
identified and whether the yield of respiratory pathogens as a whole increases compared to the 
current practice of CS alone. Additionally, it would be important to ask children, their families 
and staff whether they would be happy to perform CS and CP routinely to ensure that this 
research has the potential to be applied clinically. 
There would be numerous barriers to conducting a study as outlined above. Cost implications 
would be important to consider, as although CP are relatively cheap, funding would be required 
to cover these costs. This study would also potentially require collaboration between not only 
CF centres but also microbiology departments and all departments would need to have access 
to the same agar plates which can vary between hospitals. Ethical approval would also be 
needed.  
However, in spite of some of the challenges, performing both CS and CP has the potential to 
identify more pathogens than CS alone and may allow for earlier detection of P. aeruginosa 
which causes airway damage, increased morbidity and earlier mortality in children with CF. 
Hence, ascertaining whether the addition of CP in clinics is beneficial should be a research 
priority.   
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6.7 Recommendations for clinical practice  
This service evaluation has highlighted key points to consider in clinical practice:  
• CS and CP are both valid methods for routine identification of respiratory infections in 
non-expectorating children with CF.  
• Taking duplicate samples from non-expectorating children may increase yield of 
pathogens. 
There is insufficient evidence from this service evaluation to recommend the use of CP instead 
of CS and vice versa. This argument is reinforced by inconclusive past literature comparing CS 
and CP (146–149). However, this study indicates that performing multiple samples increases 
pathogen detection rates and as such a recommendation from this study could be to take both 
CS and CP from non-expectorating patients. Further work on whether taking duplicates CS or 
CP can improve identification of pathogens is required before recommendation for changing 
current clinical practice can be made. 
6.8 Conclusions  
Respiratory complications are the leading cause of morbidity and mortality in individuals with 
CF and identification and treatment of respiratory infection is vital in managing CF related lung 
disease. Routine samples should be taken at every outpatient appointment to identify 
pathogens, as some children may be asymptomatic, and presentations of pulmonary 
exacerbations and chronic infections differ with every child. In most children and adults, sputum 
cultures are the optimal method for identifying respiratory infections. However, this is not 
possible in all patients, particularly in young children who may be unable or unwilling to 
expectorate.  
Nearly all CF centres in the UK use CS as the method of choice for routine surveillance cultures 
in non-expectorating children. However, CP have been explored as an alternative. In this service 
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evaluation the addition of CP increased the yield of pathogens from 10% when using just CS 
to 18% when using both CS and CP.  
A greater number of pathogens were grown from CP compared to CS, but CS identified more 
different types of probable pathogens. Although statistically superior, it is not possible to 
confidently determine whether CP are superior to CS in indentifying pathogens clinically. 
However, it is evident from this study is that duplicate CS and CP samples improve identification 
of pathogens. Subsequent research is required to establish whether taking multiple CS or CP 
samples or increased sampling frequency has similar improvements for pathogen identification.  
The addition of CP also has the potential to identify more early cases of P. aeruginosa. 
Although the numbers of young children identified in this study were small, cases of P. 
aeruginosa would have been missed without the addition of CP. Due to the small population 
included in this study, further work is required to determine whether these results translate to 
a larger population of patients and are generalisable. 
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7.0 Appendix 
Appendix A 
 
Appendix B 
Contingency tables used in the calculation of McNemar’s test taking only one sample from each 
patient from the second to tenth sample provided from each patient. 
Second sample 
 Cough Plate  
Cough Swab  Negative Positive 
Negative 4 1 
Positive 2 30 
Chi-squared = 0.33 
McNemar’s significance probability = 1.000 
Third sample 
 Cough Plate  
Cough Swab  Negative Positive 
Negative 2 1 
Positive 2 32 
Chi-squared = 0.33 
McNemar’s significance probability = 1.000 
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Fourth sample 
 Cough Plate  
Cough Swab  Negative Positive 
Negative 3 2 
Positive 3 27 
Chi-squared = 0.20 
McNemar’s significance probability = 1.000 
 
Fifth sample  
 Cough Plate  
Cough Swab  Negative Positive 
Negative 3 1 
Positive 4 24 
Chi-squared = 1.80 
McNemar’s significance probability = 0.375 
Sixth sample  
 Cough Plate  
Cough Swab  Negative Positive 
Negative 3 0 
Positive 1 25 
Chi-squared = 1.00 
McNemar’s significance probability = 1.000 
 
Seventh sample  
 Cough Plate  
Cough Swab  Negative Positive 
Negative 0 1 
Positive 1 26 
Chi-squared = 0.00 
McNemar’s significance probability = 1.000 
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Eighth sample  
 Cough Plate  
Cough Swab  Negative Positive 
Negative 2 0 
Positive 2 23 
Chi-squared = 2.00 
McNemar’s significance probability = 1.000 
 
Ninth sample 
 Cough Plate  
Cough Swab  Negative Positive 
Negative 1 4 
Positive 2 19 
Chi-squared = 0.67 
McNemar’s significance probability = 0.688 
Tenth sample 
 Cough Plate  
Cough Swab  Negative Positive 
Negative 2 3 
Positive 2 19 
Chi-squared = 0.20 
McNemar’s significance probability = 1.000 
 
 
 
